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SUMMARY 
The increased iron has been implicated as a major generator of reactive 
oxygen species (ROS), which can cause neuronal death in neurodegenerative 
diseases. However, the mechanism of misregulation of iron in neurodegeneration 
is still not clear. The present study was carried out to elucidate the distribution of 
divalent metal transporter-1 in monkey basal ganglia.  Kainate intracere-
broventricular injection in rat brain resulting in neurodegeneration is widely used 
as a model of neurodegeneration. Using this animal model, the present study 
was also carried out to elucidate the expression of iron handling proteins such as 
divalent metal transporter-1 (DMT1) isoforms, iron regulatory proteins (IRPs), 
and ferritin in the kainate lesioned hippocampus. 
In monkey basal ganglia, regions such as the caudate nucleus, putamen, 
and substantia nigra pars reticulata contained dense staining of DMT1 in 
astrocytic processes, and were also observed to contain large numbers of 
ferrous iron granules. The high levels of DMT1 in these regions may account for 
the high levels of iron in these regions, indicating that DMT1 may play an 
important role in iron uptake in brain. 
A sustained, upregulation of IRP1, IRP2, DMT1 and -IRE DMT1 protein 
was detected in astrocytes in the kainate lesioned hippocampus. The increased 
DMT1 may play an important role in iron uptake in the degenerating brain, while 
increased IRPs expression could lead to increased expression of the +IRE form 
of DMT1.   
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An increase in ferritin expression, and increased level of ferric iron and 
ferrous iron were also observed in microglia and oligodendrocytes in the kainate-
lesioned hippocampus. An increase in iron, together with a reduced expression 
of iron binding proteins such as ferritin particularly at later time intervals after 
kainate lesions, could result in some of the iron being present in the ferrous form, 
capable of generating free radicals.  
Increased expression of the iron transporters, ferroportin-1 and 
ceruloplasmin was also observed after kainate injection. The upregulation of 
these proteins may result in iron efflux from astrocytes to other neural cells, 
resulting in further damage to the brain. 
Heme oxygenase-1 can cleave the heme molecule to produce free ferrous 
iron and plays an important role in iron homeostasis. Both increased heme 
oxygenase-1(HO-1) and bilirubin, the product of HO-1 catalyzed reactions, were 
observed in damaged neurons at early time intervals, and astrocytes at later time 
intervals after kainate injection.  HO-1 induction had a net protective effect on 
neurons in the kainate model of excitotoxic injury, though it can catalyze heme to 
release ferrous iron. 
 The misregulation of iron handling proteins would lead to abnormally high 
iron accumulation in kainate lesioned hippocampus, which generate reactive 
oxidative stress and further contribute to neuronal cell death. The results from the 
study shed light on the misregulation of iron handling proteins in kainate-induced 
neuronal injury, and are useful for further understanding the mechanism of iron 
 XVII
accumulation involved in the pathobiology of neurodegeneration. These also 
provide clues to the development of pharmaceutical strategies to treat 
















1. General introduction: iron in the human body      
Iron is vital for all living organisms because it is essential for multiple 
metabolic processes to induce oxygen transport, DNA synthesis and electron 
transport. However, iron must be either bound to protein or kept in the trivalent 
redox state in order to prevent tissue damage from free radical formation 
(McCord 1998). Thus absorption, concentrations of iron in body organs and the 
redox state of iron must be carefully regulated. Too little iron produces iron-
deficiency anemia, whereas excess iron causes siderosis and organ damage. 
Understanding iron regulation and its role in diseases and injury is the focus of 
the studies.  
Iron represents approximately 35-45 mg/kg of the body in adult man or 
woman. In the balanced state, 1 to 2 mg of iron enters and leaves the body each 
day. Dietary iron is absorbed by duodenal enterocytes and circulates in plasma 
bound to transferrin. Most of the iron in the body is incorporated into hemoglobin 
in erythroid precursors and mature red cells. Approximately 10 to 15 percent is 
present in muscle fibers (in myoglobin) and other tissues (in enzymes and 
cytochromes). Iron is stored in parenchymal cells of the liver and 
reticuloendothelial macrophages. These macrophages provide most of the 
usable iron by degrading hemoglobin in senescent erythrocytes and reloading 
ferric iron onto transferrin for delivery to cells (Andrews 1999a). 
Being one of the most abundant metals in the human body, iron plays 
important roles in cellular processes such as the synthesis of DNA, RNA, and 
protein, electron transport, cellular respiration, cell proliferation and differentiation, 
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and regulation of gene expression (Boldt 1999; Conrad et al. 1999; Wessling-
resnick 1999). Iron is found in the active centers of many enzymes and oxygen 
carrier proteins. It is a key component of cytochromes a, b, and c, cytochrome 
oxidase and the iron-sulfur complexes of the oxidative chain and is therefore 
important for producing adenosine triphosphate (ATP) (Poss and Tonegawa 
1997; Wigglesworth and Baum 1988). Ribonucleoside reductase, the rate-limiting 
enzyme of the first metabolic reaction committed to DNA synthesis, succinate 
dehydrogenase and aconitase of the tricarboxylic acid (TCA) cycle, are also Fe-
dependent enzymes (Wigglesworth and Baum 1988; Pinero and Connor 2000). 
The brain’s iron requirement is relatively high, consistent with its high 
demand for ATP in the brain to maintain membrane ionic gradients, synaptic 
transmission, and axonal transport (Beal 1998). Furthermore, iron is a cofactor 
for the enzymes tyrosine hydroxylase and tryptophan hydroxylase, which are 
involved in the synthesis of neurotransmitters (Chen et al. 1995). In addition, iron 
is essential for the biosynthesis of lipids and cholesterol, which are important 
substrates in the synthesis of myelin, as well as for metabolic enzymes whose 
concentration is elevated in oligodendrocytes (Dwork et al. 1988; Connor and 
Menzies 1990; LeVine and Macklin 1990). Iron is needed as a cofactor for the 
production of the neurotransmitter dopamine, which is affected in Parkinson’s 
disease patients, and norepinephrine and serotonin, which play a significant role 
in the mood disorders (Hill et al. 1985; Youdim et al. 1990; Beard et al. 1993a, b).  
Iron is also reportedly involved in GABAergic system activity (Taneja et al. 1990), 
 3
and critical for learning and memory (Youdim et al. 1989, 1990; Gerlach et al. 
1994). 
Cellular iron homeostasis necessitates tight control of iron uptake, storage, 
export and management of intra-cellular iron homeostasis. Iron homeostasis is 
maintained by several iron handling proteins as follows: 
(1) Iron uptake: Iron uptake into cells is through Iron transport proteins 
such as transferrin (Tf), transferrin receptor (TfR), divalent metal 
transporter-1(DMT1). Ferric iron in plasma is bound to Tf, which 
has two iron-binding domains that bind the ferric form of iron with 
very high affinity. Diferric-Tf binds its receptor (TfR) in the cell 
membrane and the complex is internalized into the cell. Another 
iron transport protein, DMT1, potentially transports other divalent 
cations including Fe2+, Zn2+, Mn2+, Cu2+, and Pb2+ into cells. 
(2) Iron storage: After iron enters into cells, iron can be stored in the 
iron storage protein ferritin. Ferritin is capable of storing 
(sequestering) up to 4500 Fe3+ atoms.  
(3) Iron export: Iron in cytoplasm can be exported by ferroportin-1       
(IREG1, MTP1). Ceruloplasmin (Cp) is also thought to be involved 
in iron export.                                                          
(4) Iron management: Iron levels within the cell are tightly regulated by 
the activity of cytosolic iron regulatory proteins (IRPs) 1 and 2 which 
bind to RNA motifs named iron responsive elements (IREs). The 
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mRNAs of TfR, DMT1 and ferritin all contain IREs and are 
regulated by IRPs (Zecca et al. 2004).  
(5) Other related iron handling proteins: such as Heme oxygenase-1 
(HO-1). 
The biological importance of iron is in its chemistry. Existing in both 
ferrous (Fe2+) and ferric (Fe3+) oxidation state, iron is capable of accepting and 
donating electron. Therefore, iron can participate in the oxidation-reduction 
reaction known as the Fenton reaction (Wessling-Resnick 1999). In 1970, 
Beauchamp and Fridovich (Beauchamp and Fridovich 1970) proposed that the 
toxicity of O2•- and H2O2 in vivo might relate to their conversion into the powerfully 
reactive hydroxyl radical. Transition metal ions such as iron and copper can 
catalyze this conversion: 
       Fe2++H2O2→Fe3++OH−+OH•                                (the Fenton reaction) 
O2•- converts Fe3+ into Fe2+, and so recycles the Fe (Halliwell and 
Gutteridge 1990). 
     O2•- + Fe3+ = O2 + Fe2+     
 Excess iron is highly toxic, because it is able to generate reactive oxygen 
species (ROS). ROS can react rapidly with high affinity with almost every 
molecule found in living cells. The net effects are DNA damage, impaired 
synthesis of proteins, membrane lipids, and carbohydrates, induction of 
proteases and altered cell proliferation, which can severely impair cellular 
integrity and cause cell death. Iron accumulation in tissues, (particularly if the 
labile iron pool is increased), is associated with tissue damage (McCord 1998). 
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 The concentration of iron in the brain is region dependent and is normally 
elevated in specific central nervous system (CNS) nuclei including the globus 
pallidus, substantia nigra, and dentate nucleus. Abnormally high levels of iron 
concentration and oxidative stress have been demonstrated in a number of 
neurodegenerative disorders, such as Alzheimer’s disease (AD) and Parkinson’s  
disease (PD), and less common disorders such as Huntington’s chorea and 
Hallervorden–Spatz syndrome. The increased level of brain tissue iron has been 
implicated as a major generator of reactive oxygen species (ROS), which can 
cause neuronal death in neurodegenerative diseases (Connor et al. 2001a). 
 
2. Iron homeostasis and iron handling proteins 
 Since iron is vital for a number of diverse cellular functions, a constant 
balance between iron uptake, transport, storage, release, and post-transcriptional 
control is required to maintain iron homeostasis. Vertebrates have evolved 
distinct, highly specialized mechanisms for this purpose. This following section 
discusses the pathways of iron metabolism, which are participated by several 
iron handling proteins. 
 
2. 1. Iron uptake  
 2. 1. 1. Transferrin and transferrin receptor 
 The 80-kDa protein transferrin (Tf) is responsible for the majority of 
cellular iron delivery in the body. Tf has two iron binding domains that bind the 
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ferric form of iron with very high affinity (Aisen and Listowsky 1980).  Under 
normal circumstances, plasma Tf is normally 25-50% saturated with iron 
(Bothwell et al. 1958), and there is no free iron in serum because abundant 
serum transferrin (approximately 20 mM/L) binds ferric iron (Baker and Morgan 
1994). By fully coordinating the bound iron, serum transferrin ensures that iron is 
not chemically reactive, and the size of transferrin ensures that iron is not lost 
through filtration in the kidneys (Aisen 1994). 
 In this form, iron is nonreactive, but also difficult to extract. To deal with 
this, there are several Tf-dependent iron uptake mechanisms that mediate 
internalization of the entire iron protein complex. The uptake of diferric-Tf via TfR 
has been most intensively studied (Cheng et al. 2004). The TfR is a homodimeric 
glycoprotein, its two subunits linked by a paired of disulfides bond at or near the 
intramembranous portion of the molecule. On binding of diferric transferrin to the 
receptor, the membrane surrounding the TfR-transferrin complex invaginates 
within clathrin-coated pits to form early endosomes (Odorizzi and Trowbridge 
1997). Endosomal acidification facilitates the release of iron from transferrin. An 
unidentified ferrireductase subsequently reduces Fe3+ to Fe2+, allowing divalent 
metal transporter 1 (DMT1; also known as DCT1 or NRAMP2) to transfer Fe2+ 
across the endosomal membrane into the cytoplasm (Fleming et al. 1998). The 
apotransferrin-TfR receptor complex then recycles into the plasma membrane, 
apotransferrin dissociates from the TfR at neutral pH, and the TfR is free to 
participate in another cycle of iron uptake. Thus under normal conditions, 
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individual cells in the systemic circulation can regulate iron uptake effectively by 
regulating expression of the TfR (Rouault and Klausner 1997). 
 A transferrin receptor homologous protein, transferrin receptor-2 (TfR2) 
(Kawabata et al. 1999), is restricted to hepatocytes, duodenal crypt cells, and 
erythroid cells, suggesting a more specialized role. The finding that mutations in 
the human TfR2 gene result in hemochromatosis (pathological systemic iron 
overload) (Camaschella et al. 2000) established its importance in iron 
homeostasis. TfR2 binds Tf with approximately 30-fold lower affinity than TfR 
and, in contrast to TfR, its expression is not controlled by the IRE/IRP regulatory 
system (Hentze et al. 2004). 
Non-heme iron circulates in the blood mainly in the form of transferrin-
ferric iron (Tf-Fe) complexes. In other parts of the body, Tf-Fe can be transported 
from the vasculature paracellularly, due to the lack of endothelial cell tight 
junctions. However, the tightness of the blood brain barrier (BBB) precludes any 
significant paracellular transport. A specific TfR is necessary to accept the Tf-Fe 
complex from the blood. Iron transport across the blood brain barrier and 
neuronal iron uptake involves the Tf receptor. TfR have been demonstrated on 
blood vessels and neurons in brain (Broadwell et al. 1996; Kissel et al. 1998; 
Moos et al. 1998; Dickinson and Connor 1998). Tf binds its receptor (TfR) and 
the complex is internalized into the endothelial cells and the iron is released into 
the cytoplasm from the endosome (Burdo and Connor 2003).  
 Immunohistochemical studies demonstrated a significant loss of TfR-
binding (about 60%) similar to the degree of neuronal loss (about 80%; Morris et 
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al. 1994a), and a decrease in Tf-binding sites on perikarya of melanized neurons 
in the SN of Parkinsonian brains (Faucheux et al. 1997). Thus accumulation of 
iron in the SN in PD does not seem to depend upon increased Tf or TfR. Studies  
also showed that iron is transported across the blood brain barrier at a greater 
rate than transferrin (Banks et al. 1988). When levels of CSF iron and transferrin 
are measured, there is often a molar excess of iron relative to transferrin iron-
binding capacity, implying that there may be nontransferrin-bound iron (NTBI) in 
brain (Bradbury 1997; Moos and Morgan 1998).  
 This is further supported by the findings in hypotransferrinemic mice, 
which show a normal distribution of iron in the brain (Dickinson and Connor 1995; 
1998; Beard et al. 2005). These data suggest that non-transferrin mediated 
mechanisms are likely to be involved in iron influx into cells in the brain. It has 
been shown that astrocytes can indeed take up iron through a non-transferrin 
mediated mechanism, which is thought to be mainly mediated by DMT1 (Jeong 
and David 2003). 
 
  2. 1. 2. Divalent metal transporter-1 (DMT1)  
 There is strong evidence that cells must also express a Tf-independent 
iron transport system. Intestinal absorptive cells take up dietary non-Tf bound 
iron directly, through the action of DMT1, the same metal transporter that 
mediates iron export from the endosome following uptake via the Tf cycle 
(Fleming et al. 1997; Gunshin et al. 1997).  
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 Divalent metal transporter-1 (DMT1), previously known as natural 
resistance associated macrophage protein 2 (NRAMP2), was first identified in 
1995, in a screen for homologs of NRAMP1, a protein involved in host defence 
(Garrick et al. 2003). It is now clear that DMT1 is a metal transporter which 
mediates active proton-coupled transmembrane transport including the transport 
of iron not only across the cell membrane but also out of the endosomes 
(Andrews 1999b). DMT1 has an unusually broad substrate range including Fe2+, 
Mn2+, Cu2+, Pb 2+, etc. (Gunshin et al. 1997). 
 There are at least two different splice forms that differ at their 3' 
untranslated region by either the presence or absence of an iron response 
element (IRE) (+IRE and –IRE isoforms respectively) (Lee et al. 1998; Lam-Yuk-
Tseung and Gros 2006). The two protein isoforms also differ in the last 18 or 25 
amino acids of the C termini. –IRE DMT1 encodes a protein in which the C-
terminal 18 amino acids derived from +IRE mRNA are replaced by a novel 25-
amino acid segment. Recently, Hubert and Hentze (2001) have drawn attention 
to the 5’- end of the mRNA and protein. There they found an alternative exon to 
exon 1 of human DMT1 so they have dubbed the new sequence 1A (the old 
becoming an untranslated 1B and the next exon remaining as 2). Now it is 
possible to consider four alternative splice isoforms (Lis et al. 2005).  The tissue 
localization and functional significance of the four isoforms remain to be reported.  
 Two research groups (Kishi and Tabuchi 1997; Lee et al. 1998) have 
reported the promoter region of the human DMT1 (NRAMP2) gene. Computer 
analysis revealed no significant sequence homology with the human NRAMP1 
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promoter (Kishi et al. 1996). Further analysis of the 5’ flanking sequence with the 
Web Signal Scan Program (http://www.dna.affrc.go.jp/htdocs/sigscan/ 
signal.html) showed various hypothetical sites including that of AP-1, NF-κB and 
Sp1, metal response elements (MRE), potential γ-interferon (γ-IFN) responsive 
element, hypoxia-inducible factor-1(HIF-1). It has reported that age-dependent 
but iron-independent expression of two mRNA isoforms of divalent metal 
transporter 1 in rat brain (Ke et al. 2005). 
 The biological function of DMT1 has been determined through 
phenotypic analysis of two animals, Microcytic anemia (mk) mice and Belgrade 
(b) rats, with spontaneous mutations in DMT1 (Fleming et al. 1997; 1998; Moos 
and Morgan 2004).  These mutations result in severe impairment of iron transport 
function (Su et al. 1998), which indicates that DMT1 is important for both of these 
iron transport steps. DMT1 transports divalent (ferrous) iron, most likely produced 
by the reduction of ferric iron at the cell surface, or within an endosomal 
compartment. It may be responsible for iron uptake from the gut into the 
enterocytes and for removal of iron from endosomes within cells (LeVine and 
Macklin 1990). The hematologic phenotype of a child, compound heterozygote 
for 2 DMT1 mutations has been reported, who was affected by severe anemia 
since birth and showed hepatic iron overload. The novel mutations were a 3-bp 
deletion in intron 4 (c.310-3_5del CTT) resulting in a splicing abnormality and a 
C>T transition at nucleotide 1246(p. R416C) (Iolascon et al. 2006)  
 The expression of DMT1 in intestinal cells has been shown to be 
regulated in response to iron status. The putative promoter of the human DMT1 
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gene contains several potential metal response elements (MRE), AP-1, and NF-
κB, suggesting that there may be transcriptional regulation in response to metal 
levels (Lee et al. 1998). It is likely that there is also post-transcriptional 
regulation. The IRE sequence found in the 3′ untranslated region (UTR) of one 
isoform of DMT1 mRNA binds IRPs in vitro and appears to respond to cellular 
iron levels (Gunshin et al. 1997). IRPs would bind under low iron conditions, and 
stabilize the DMT1 mRNA, leading to an increase in the amount of DMT1 protein 
produced. 
 In addition to iron, oxidants and hypoxia can activate the expression of 
DMT1 (Rouault 2002). Pro-inflammatory cytokines, tumor necrosis factor (TNF)- 
α, interferon (IFN) -γ and LPS have been demonstrated to affect an elevated 
expression of DMT1 in vitro (Moldawer et al. 1989; Ludwiczek et al. 2003; Wang 
et al. 2005).  
        The distribution of DMT1 in the cerebral cortex is found in endothelial 
cells lining the blood vessels and in astrocytic end feet around blood vessels 
(Burdo et al. 1999).  This indicates that following endocytosis, iron is removed 
from the endosome within the endothelial cell via DMT1. The released iron in is 
escorted by currently unknown mechanisms to the abluminal membrane for 
transport into the astocytic end-foot process via DMT1 (Burdo and Connor 2003). 
Belgrade rats, which have a defect in DMT1, have dramatically less stainable 
iron in the brain than is normal (Burdo et al. 1999), indicating DMT1 is directly 
involved in brain iron uptake. Increased divalent metal transporter 1 expression 
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has been found to be associated with the neurotoxicity of L-DOPA in in C6 
glioma cells, which may be involved in pathogensis of PD (Chang et al. 2006)  
 
2. 1. 3. Other iron uptake proteins 
Lactoferrin (Lf)  
 Lactoferrin (Lf) is a member of the Tf family and could be involved in brain 
iron transport. The affinity constant of Lf for iron is 300 times greater than that of 
Tf and it may retain iron under more acidic conditions than Tf. Lf uptake into cells 
is receptor mediated. Lf receptors have been reported on intestinal cells, 
neurons, cerebral vasculature and some glial cell types (Faucheux et al. 1995; 
Qian and Wang 1998). Double labeling of Lf and iron demonstrated transcytosis 
of intact holo Lf across the endothelial cell monolayer. Lf receptors have also 
been reported on neuromelanin cells in the substantia nigra (Faucheux et al. 
1995). Lactoferrin is present in the normal human cortex, but is present at higher 
levels in neurodegenerative diseases such as Parkinson’s disease (Leveugle et 
al. 1996).  
 
Melanotransferrin (p97) 
 The melanotransferrin molecule, also called p97 (human melanoma 
tumor-associated antigen), was first identified on the surface of melanoma cells 
(Brown et al. 1981). This protein is a homologue of transferrin and belongs to the 
important group of iron binding proteins that include serum Tf, lactoferrin Lf and 
ovotransferrin. In addition to expression on melanoma cells, MTf has been 
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reported to be expressed by a wide range of cultured normal cell types such as 
liver cells and intestinal cells (Sciot et al. 1989; Alemany et al. 1993). It has also 
been reported to be present in the brain (Rothenberger et al. 1996; Yamada et al. 
1999), and may play a physiological role in iron transport within the human brain. 
Overexpression of MTf may be involved in excess iron accumulation in the brain 
and hence associated with the development of Alzheimer’s disease. Serum 
melanotransferrin, p97 has been thought as a biochemical marker of Alzheimer's 
disease (Kennard et al. 1996; Jefferies et al. 1996; Yamada et al. 1999; Kim et al. 
2001). 
                                                                                       
Hemochromatosis protein (HFE) 
 Hereditary haemochromatosis is the most common form of inherited iron 
overload in Caucasians. It is due to two mutant alleles, usually Cys282Tyr, of the 
hereditary hemochromatosis protein (HFE) gene (Feder et al. 1996), which leads 
to iron overload disease in homozygotic and some heterozygotic individuals. HFE 
is a membrane protein that can influence cellular iron uptake (Arredondo et al. 
2001; Griffiths et al. 2001; Ludwiczek et al. 2005). HFE has recently been 
localized to brain vasculature, choroid plexus and ependymal cells that line the 
ventricles (Connor et al. 2001b). Indirect measurements of iron using MRI found 
increased iron in the lentiform nucleus in individuals with hemochromatosis (Berg 
et al. 2000). Carrying one or more of the HFE mutations has recently been 
reported to influence the onset of Alzheimer’s disease (Moalem et al. 2000; 
Sampietro et al. 2001, Berlin et al. 2004), and to increase the severity of gliomas 
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(Martinez di Montemuros et al. 2001). The increase in onset of AD accompanying 
an HFE mutation is consistent with the reported role of iron in AD (Connor et al. 
1992a,b). 
 
2. 2. Iron storage protein:  ferritin 
 Iron that is not utilized immediately in the cell is stored in ferritin, which is a 
ubiquitous and highly conserved iron binding protein. In vertebrates, the cytosolic 
form of ferritin consists of 2 subunits, termed H and L, which are encoded by 
separate genes (Caskey et al. 1983; Worwood et al. 1985). Twenty-four ferritin 
subunits assemble to form the apoferritin shell. Each apoferritin molecule of 450 
kDa can sequester up to approximately 4500 iron atoms (Harrison and Arosio 
1996; Bou-Abdallah et al. 2005). Depending on the tissue type and physiologic 
status of the cell, the ratio of H to L subunits in ferritin can vary widely. Ferritin 
also has enzymatic properties, converting Fe2+ to Fe3+ as iron is internalized and 
sequestered in the ferritin mineral core. The ferroxidase activity is dramatically 
reduced following mutation of residues His65 and Glu62 in both human and 
mouse (Lawson et al. 1989; Rucker et al. 1996). Ferritin, by capturing and 
"buffering" the intracellular labile iron pool (Rucker et al. 1996; Picard et al. 1996, 
1998; Kakhlon et al. 2001), plays a key role in maintaining iron homeostasis 
(Wilkinson et al. 2006). The critical roles of ferritin in cellular and organismal iron 
homeostasis are iron sequestration and to limit Fe2+, which participates in the 
generation of ROS. 
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 The content of cytoplasmic ferritin is regulated by the translation of ferritin 
H and L mRNAs in response to an intracellular pool of "chelatable" or "labile" iron 
(Aziz and Munro 1986; Rogers and Munro 1987). Thus, when iron levels are low, 
ferritin synthesis is decreased; conversely, when iron levels are high, ferritin 
synthesis increases. The regulatory response of ferritin to iron is largely 
posttranscriptional (Zahringer et al. 1976). This process is mediated by iron 
regulatory proteins 1 and 2 (IRP1 and IRP2), which bind to IRE and inhibit mRNA 
translation (See Iron regulatory protein section). 
 In addition to iron, both transcriptional and posttranscriptional mechanisms 
have been implicated in ferritin induction by oxidants. Oxidative stress can also 
contribute to ferritin induction by inactivating IRP1 through reversible oxidation of 
critical cysteine residues (Cairo et al. 1996). The cytokine tumor necrosis factor 
alpha (TNF-α) and interleukin 1 (IL-1) transcriptionally induce the H chain of 
ferritin, suggesting that pathways related to inflammation and stress can impact 
on ferritin regulation (Torti et al. 1988; Wei et al. 1990; Zhang et al. 2005). 
 Ferritin is made in the brain. Based on immunohistochemical analysis, 
neurons contain more H-ferritin than L-ferritin, and microglia contain more L-
ferritin. Oligodendrocytes have both H-ferritin and L-ferritin (Connor et al. 1994; 
1995b; Connor and Menzies 1995).The ratio of H-ferritin to L-ferritin in the brain 
is region-specific and the ratio is influenced by iron deficiency and iron 
supplementation (Han et al. 2000). There is an age-related increase in ferritin in 
both rat and normal human brains (Connor et al. 1995a; Focht et al. 1997), but 
not when aging is associated with Alzheimer’s disease or Parkinson’s disease 
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(Connor et al. 1995b; Connor 1997). The inability of ferritin to increase to 
sequester sufficient quantities of iron with age is likely due to the increased iron-
induced oxidative stress seen with these diseases (Connor 1997; Shinobu and 
Beal 1997; Thompson et al. 2001). It has reported that a mutation in the ferritin 
light polypeptide gene and disfunction of ferritin are associated with 
neurodegenerative diseases (Vidal et al. 2004; Quintana et al. 2006).  
 
2.3. Cellular iron export  
2. 3. 1. Ferroportin-1 (IREG1, MTP1) 
 Duodenal entrecotes, macrophages, hepatocytes, placenta 
syncytiotrophoblasts, and cells of the central nervous system (CNS) require 
mechanisms to release iron in a controlled fashion to ensure availability of the 
metal where it is needed. The only putative iron exporter identified to date is 
ferroportin-1 (FP; also known as IREG1, MTP) (Abboud and Haile 2000; 
Donovan et al. 2000; McKie et al. 2000; Ganz 2005). Mouse ferroportin-1 cDNA 
encodes a protein 570 amino acids in length with a predicted mass of 62 kDa. 
Human ferroportin-1 shows little homology to the iron importer DMT1 (NRAMP2). 
Sequence analysis of ferroportin-1 mRNA revealed the presence of an iron 
response element (IRE) in its 5’ untranslated region (Abboud and Haile 2000; 
Donovan et al. 2000; McKie et al. 2000). Ferroportin-1 is located at the 
basolateral membrane of duodenal enterocytes, where it mediates iron export 
into the bloodstream, apparently in concert with hephaestin, a ferroxidase that is 
homologous to the abundant plasma protein ceruloplasmin (Vulpe et al. 1999). 
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Hephaestin may interact with the iron chaperone to facilitate iron transfer to 
ferroportin-1. Iron export from nonintestinal cells requires ceruloplasmin (Cp) 
(Harris et al. 1999). Cp converts Fe2+, likely exported by ferroportin-1, to Fe2+ that 
is loaded onto Tf for transport in the plasma. In the brain, the 
glycosylphosphatidylinositol (GPI)-anchored form of Cp physically interacts with 
ferroportin-1 to export iron from astrocytes (Jeong and David 2003). A mutation 
in ferroportin-1 has been associated with the development of autosomal 
dominant hemochromatosis (Njajou et al. 2001; Cremonesi et al. 2005). 
 
2. 3. 2. Ceruloplasmin 
  Ceruloplasmin (Cp or the sky-blue protein) is an abundant serum alpha-2 
glycoprotein and has a molecular mass of approximately 132 kDa. This protein 
consists of a single polypeptide chain of 1046 amino acid residues and belongs 
to a family of multi-nuclear ‘blue’ copper oxidase (Hellman and Gitlin 2002). 
 Ceruloplasmin plays a critical role in the iron cycle by establishing a rate of 
iron oxidation sufficient for iron release from the reticuloendothelial system. Cp 
may function to promote iron efflux from brain cells via ferroxidase activity 
(converting Fe2+ to Fe3+). The absence of serum ceruloplasmin in patients with 
aceruloplasminemia for mutations in the ceruloplasmin gene (Harris et al. 1995; 
Yoshida et al. 1995a) leads to severe iron loading in the brain, particularly in the 
basal ganglia. The implications are that ceruloplasmin is required for iron 
mobilization from cells. 
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 Although the liver is the predominant source of serum ceruloplasmin, 
extrahepatic ceruloplasmin gene expression has been demonstrated in many 
tissues including spleen, lung, testis, and brain (Aldred et al. 1987; Klomp et al. 
1996; Yang et al. 1996).Recent studies demonstrate that ceruloplasmin is 
synthesized as a glycophosphatidylinositol (GPI)-anchored protein generated by 
alternative splicing of exons 19 and 20 in astrocytes and Sertoli cells (Patel and 
David 1997; Salzer et al. 1998; Patel et al. 2000).The glycosylphosphatidyli-
nositol(GPI)-anchored form of Cp physically interacts with ferroportin-1 to export 
iron from astrocytes (Jeong and David 2003). 
  
2. 4. Iron regulatory proteins   
 Proteins involved in iron uptake, storage, utilization, and export must be 
regulated in a coordinated fashion. The regulatory mechanisms that orchestrate 
their expression involve modulation of transcription, mRNA stability, translation, 
and posttranslational modifications. In mammalian iron metabolism, ferritin, TfR, 
DMT1, ferroportin-1 and several other iron metabolism genes are post-
transcriptionally regulated, which is best characterized. 
  Iron regulatory proteins 1 and 2 are cytosolic proteins that bind to RNA 
stem-loops known as iron responsive elements (IRE) (Hentze and Kuhn 1996) in 
several transcripts. IREs contain a particular combination of structural elements 
and sequence features. These include a sixmembered loop with the sequence 
5’CAGUGX-3’ (Fig I, page 19) features that are likely critical in high-affinity IRP 
binding (Addess et al. 1997). In some transcripts, such as those that encode 
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ferritin H and L subunits, a single IRE is found near the 5’ untranslated region 
(UTR) of the transcript. When either IRP binds to an IRE positioned near the cap 
site (a modification of the first nucleotide of the transcript), binding of translational 
initiation factors to the cap site is blocked by steric hindrance, and new protein 
synthesis is inhibited (Gray and Hentze 1994). In the TfR transcript, there are five 
IREs in the 3’ untranslate region (UTR), and IRP binding protects the transcript 
from endonucleolytic cleavage and degradation (Binder et al. 1994). As a result, 
TfR transcript levels increase, leading to a concomitant increase in TfR 
biosynthesis. An IRE is found in the 3’ UTR of an isoform of DMT1 (Gunshin et al. 
1997), and the 5’UTR of the recently identified iron exporter ferroportin-1/IREG1/ 
MTP1 (Abboud and Haile 2000; Donovan et al. 2000; McKie et al. 2000). An IRE-
like sequence is also found within the coding region of the APP mRNA in a 
region where mutations associated with familial AD have been reported 
(Chartier-Harlin et al. 1991; Murrell et al. 1991). 
 IRP1 and IRP2 are homologous cytoplasmic polypeptides of 889 and 964 
amino acids, respectively, and belong to the family of iron-sulfur cluster 
isomerases (Eisenstein 2000). IRP1 is regulated by an unusual iron-sulfur cluster 
switch (Haile et al. 1992a, b). In iron-replete cells, it assembles a cubane 4Fe-4S 
cluster, which inhibits its IRE-binding activity. Moreover, this cluster converts 
IRP1 to a cytosolic aconitase. Thus, IRP1 is a bifunctional protein. In iron-
depleted cells, oxidative degradation of the 4Fe-4S cluster takes place, cytosolic 
aconitase activity is lost and the apoprotein accumulates. The apoprotein binds 
to RNA stem-loops known as iron responsive elements (IREs) in iron metabolism 
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transcripts, repressing ferritin synthesis, and increasing TfR mRNA levels 





FIGURE I (A) The consensus IRE motif. It consists of a hexanucleotide loop (5'-
CAGUGN-3') and a stem, interrupted by a bulge with an unpaired C residue. 
Base pairing between C1 and G5 is functionally important. N6 could be any 
nucleotide, but not G, which would potentially disrupt C1-G5 interaction by C1-G6 
pairing. The bulge may consist of an asymmetric tetranucleotide, as in many 
ferritin mRNAs (left), or a single C residue (right). (B) Regulation of TfR and 
ferritin expression by the IRE/IRP system. Decreased iron supply activates 
binding of IRPs to IREs, resulting in stabilization of TfR mRNA and translational 
inhibition of the mRNAs encoding H- and L-ferritin. These responses lead to 
increased iron uptake and reduced iron storage. Conversely, increased iron 
supply inactivates binding of IRPs to IREs, resulting in degradation of TfR mRNA 
and translation of the mRNAs encoding H- and L-ferritin. These responses lead 
to decreased iron uptake and elevated iron storage (Pantopoulos 2004). 
 
binds to IREs and regulates ferritin and TfR expression, but its mechanism for 
sensing iron status differs. It is synthesized de novo under conditions of iron 
starvation, remains stable in iron- starved or hypoxic cells, and undergoes 
proteasomal degradation in iron-replete and normoxic cells (Guo et al. 1995; Iwai 
et al. 1998). 
 
 IRP1 is expressed ubiquitously and probably this is also the case for 
IRP2. Little is known on the relative contribution of each of the IRPs in the 
maintenance of cellular iron homeostasis. The targeted disruption of IRP1 did not 
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yield any obvious phenotype (Rouault 2002). By contrast, the IRP2–/– mice 
displayed aberrant iron homeostasis and accumulated iron in the intestinal 
mucosa and the CNS (LaVaute et al. 2001; Smith et al. 2004). These data 
establish IRP2 as an important regulator of systemic iron metabolism and, 
furthermore, imply that polymorphisms associated with functional inactivation of 
IRP2 may also be relevant to human disease (Cairo and Pietrangelo 2000; 
Recalcati et al. 2005). 
IRP1 was initially appreciated as an intracellular iron sensor, but it soon 
became clear that it also responds to other stimuli. Exposure of cells to hydrogen 
peroxide (H2O2) or nitric oxide (NO) promotes removal of the cluster and thereby 
induces IRE-binding activity (Pantopoulos and Hentze 2000; Cairo and 
Pietrangelo 2000; Gonzalez et al. 2004).  IRP2 is regulated in response to iron 
and oxygen supply. IRP2 also responds to NO. However, there is some 
confusion in the literature on whether NO actually activates or inhibits IRP2 
(Fillebeen and Pantopoulos 2002).  
IRPs are present in the human brain (Hu and Connor 1996; Rodriguez 
Martinez et al. 2004), and their expression and cellular distribution is affected in 
Alzheimer’s disease (Smith et al. 1998; Pinero et al. 2000). It has been proposed 
that there is a dysfunction in the IRP system in Alzheimer’s disease resulting in 
an increased affinity between the IRP and the binding site IRE on the mRNA 
(Pinero et al. 2000), which leads to the increase in cellular iron uptake and an 
increased vulnerability to oxidative stress, both of which occur in Alzheimer’s 
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disease. An increase in affinity of IRPs to the iron responsive element (IRE) may 
also directly influence amyloid precursor protein processing (Rogers et al. 1999). 
 
2. 5. Other related iron handling proteins 
Heme oxygenases 
 Heme oxygenase (HO) is a rate-limiting enzyme in heme catabolism 
catalysing the oxidative cleavage of heme, a pro-oxidant, to three biologically 
active by-products: iron, carbon monoxide, and biliverdin/bilirubin (Tenhunen et 
al. 1968).  
 The first HO isomer identified was named HO-1. HO-1 is a 32 kDa protein 
induced by a wide variety of factors. It is also known as heat shock protein 32 
(HSP32) or inducible HO. The second isomer identified was HO-2, which has a 
molecular weight of 38 kDa (Maines 1997) and was found highly concentrated in 
the nervous system and in testes (Verma et al. 1993). HO-2 is constitutively 
expressed in neurons and it is also called constitutive or neuronal HO. The most 
recently discovered HO isomer, HO-3, with a molecular weight of about 33 kDa, 
appears to be quite similar to HO-2 although it does not have a very active 
catalytic site (McCoubrey et al. 1997). Its exact function is still unclear. 
 The HO-1 gene highly inducible by a wide array of pro-oxidant and 
inflammatory stimuli including heme, β-amyloid, dopamine, H2O2, UV light, 
transition metals, prostaglandins, Th1 cytokines, and lipopolysaccharide 
(Dennery 2000; Schipper 2000; 2004). Both isoforms of HO are inhibited by 
metal protoporphyrins such as zinc protoporphyrin-IX (ZnPP-IX) (Maines 1988). 
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Several reports have documented an increase in HO in ischemic and traumatic 
human brains (Beschorner et al. 2000), and in AD brains (Smith et al. 1994; 
Schipper et al. 1995; 2004). 
 Though it has both pro- (free iron) and antioxidant (BR) properties, the 
induction of HO activity may produce a net antioxidative effect by coupling with 
iron sequestration pathways (Ryter and Tyrrell 2000; Dore 2002). Studies 
showed that bilirubin could be an antioxidant (Stocker et al. 1987a, b; Wu et al. 
1991; Clark et al. 2000), and prevent neuronal cell death against oxidative stress 
injury in limiting infarct damage (Dore et al. 1999b; Dore and Snyder 1999), and 
HO-2 is a neuroprotective agent in the nervous system (Dore et al. 2000). The 
HO inhibition by the amyloid precursors exacerbates neuronal damage 
(Takahashi et al. 2000).  
 
3. Iron and iron management in the brain 
 The following section discusses the role of iron and iron homeostasis in 
the brain, as it pertains to neurodegenerative disorders.  
 
3. 1. Iron localization in the brain 
 Iron is the most abundant transition metal in the body and has a unique 
distribution in the brain. Iron can be detected in the ex vivo brain using 
histochemical methods and in vivo using magnetic resonance imaging (MRI). 
Each of these methods has revealed that iron is normally elevated in specific 
CNS nuclei including the globus pallidus, substantia nigra, and dentate nucleus 
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(Koeppen and Dickson 2001). Iron concentrations in the SN and the globus 
pallidus are higher than those of the liver, where iron is stored and disposed of to 
other tissues. Other brain regions where iron is found in high concentrations are 
the dentate gyrus, interpeduncular nucleus, thalamus, ventral pallidus, nucleus 
basalis, and red nucleus (Gotz et al. 2004). 
 The cells in the brain that stain most robustly for iron are oligodendrocytes. 
All white matter tracts in the brain contain iron-positive oligodendrocytes in all 
species examined to date (human, monkey, rat, mouse, pig). The presence of 
iron-rich oligodendrocytes in white matter is consistent with the quantitative 
analyses that white matter consistently has more iron than corresponding gray 
matter (Rajan et al. 1976). Although predominant in the white matter, iron-
positive oligodendrocytes are found throughout the brain including in the iron-rich 
brain nuclei, such as the substantia nigra and striatum. Intracellularly, iron in 
oligodendrocytes is found in the perikaryal cytoplasm and processes (Francois et 
al. 1981; Connor and Menzies 1996; Levine 1991).  
 In addition to oligodendrocytes, microglia are the cell type most often seen 
to accumulate stainable quantities of iron in the brain. Iron-laden microglia are 
abundant in injured brains (Sastry and Arendash 1995) but are rarely seen in 
normal brains other than as part of the developmental sequence. Iron-laden 
microglia are found in white matter of brains of patients infected with human 
immunodeficiency virus (HIV) (Gelman et al. 1992) and surrounding neuritic 
plaques in Alzheimer’s disease (Connor et al. 1992a,b; Morris et al. 1994b). 
Neither the fate of the iron that microglia accumulate nor the fate of the iron-
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laden microglia themselves is known, but over time there is a loss of iron-laden 
microglia in the animal models (Sastry and Arendash 1995). The damage models 
may help to explain the mechanisms of iron efflux from the brain.  
 
3. 2. Iron handling proteins in brain 
 The proteins responsible for maintaining iron homeostasis in the brain are 
similar to those found in other organs. The basic function of these proteins is 
reviewed in section 2 of this chapter.  
   
3. 3. The possible mechanisms for iron across the blood brain barrier 
 Blood brain barrier (BBB) separates from the brain the milieu of the 
periphery. Unlike peripheral capillaries, the BBB strictly limits transport into the 
brain through both physical (tight junctions) and metabolic (enzymes) barriers. To 
enter the brain, iron must pass through the endothelial cells lining the vasculature 
(Rubin and Staddon 1999).  
 The mechanisms of iron transport across the BBB have not yet been 
completed clarified. The accumulated evidence suggests that the Tf-TfR may be 
the major route of iron transport across the luminal membrane of the capillary 
endothelium (Bradbury 1997; Moos and Morgan 1998; Malecki et al. 1999a, b). 
Evidence shows that the uptake of Tf-Fe is through TfR-medicated endocytosis 
from blood into cerebral endothelial cells (Bradbury 1997). Endosomal 
acidification facilitates the release of iron from transferrin. An unidentified 
ferrireductase subsequently reduces Fe3+ to Fe2+, allowing DMT1 to transfer Fe2+ 
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across the endosomal membrane into the cytoplasm (Fleming et al. 1998). The 
released Fe2+ across the abluminal membrane into brain parenchyma may 
involve astrocytes. Astrocytes express DMT1 and then have the ability to take up 
Fe2+ from endothelial cells through their end foot processes on the capillary 
endothelium (Malecki et al. 1999a, b; Oshiro et al. 2000; Burdo and Connor 
2003).   
 
4. Iron in the brain diseases 
4. 1. Free radicals and iron   
4. 1. 1. Free radicals and free radicals induced damage 
 Free radicals are defined as atoms or molecules that contain one more 
orbital with single unpaired electron. Oxidative stress, in essence, refers to the 
situation of a serious imbalance between productions of reactive oxygen species 
(ROS) and reactive nitrogen species (RNS) and antioxidant defence (Halliwell 
and Gutterridge 1999). ROS include oxygen radicals such as superoxide (O2•-), 
hydroxyl (OH•), peroxyl (RO2•), alkoxyl (RO•), ect, and non-radicals derivatives of 
O2• which include hydrogen peroxide (H2O2), ozone (O3), hypochlorous acid 
(HOCl). Reactive nitrogen species include nitric oxide (NO•), nitrogen dioxide 
(NO2•) and non-radical such as nitrous acid (HNO2), peroxynitrite (ONOO-), 
dinitrogen tetroxide (N2O4), dinitrogen trioxide (N2O3), peroxynitrous acid 
(ONOOH) nitronium cation (NO2+) (Halliwell 1996; Halliwell and Gutteridge 1999). 
(Table I, Page 29, Evans and Halliwell 1999) 
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 At moderate concentrations, superoxide anion, related reactive oxygen 
species (ROS) and nitric oxide (NO) play an important role as regulatory 
mediators in signaling processes (Droge 2002). However, at high concentrations, 
free radicals and radical-derived nonradical reactive species are hazardous for 
living organisms and damage all major cellular constituents.  Free radicals have 
unpaired electrons, which makes it highly reactive, and can attack a variety of 
cell targets such as modification to cellular lipid, protein and DNA, which can lead 
to cell death (Halliwell and Gutteridge 1999). 
 




 Severe oxidative stress produces major disruption of cell metabolism, 
including DNA strand breakage and base modification, rises in intracellular "free" 
Ca2+ and activation of nucleases and cNOS (Ca2+-calmodulin regulated), damage 
to membrane ion transporters and receptors, and lipid peroxidation. Such cell 
derangement can lead to release of transition metal ions from proteins within the 
cell, such as loss of Fe2+ from mitochondria, which is able to promote OH• 
formation. These can lead to cell death and tissue damage (Evans and Halliwell 
1999).   
 
4. 1. 2.   Iron and oxidative stress 
 Iron accumulation in tissues, (particularly if the labile iron pool is 
increased), is associated with tissue damage. Such low molecular weight iron 
can act as a catalyst in the Fenton reaction (Equation 1) to potentiate oxygen 
toxicity by the generation of a wide range of free radical species, including 
hydroxyl radicals, OH•. In 1970, Beauchamp and Fridovich (1970) proposed that 
the toxicity of O2•- and H2O2 in vivo might relate to their conversion into the 
powerfully reactive hydroxyl radical. Transition metal ions such as iron and 
copper can catalyze this conversion: O2•- converts Fe3+ into Fe2+, and so recycles 
Fe (Halliwell and Gutteridge 1990) (Equation 2):                                                   .                            
 
Fe2++H2O2→Fe3++OH−+OH•                                                 (1)    Fenton reaction   
O2•- + Fe3+ → O2 + Fe2+                                                                                    (2)     
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 Hydroxyl radicals are the most reactive free radical species known and 
have the ability to react with a wide range of cellular constituents at or close to its 
site of generation, including amino acid residues, purine and pyrimidine bases of 
DNA, as well as attacking membrane lipids to initiate a free radical chain reaction 
known as lipid peroxidation (Crichton et al. 2002). 
 
4. 1. 3. Brain is highly susceptible to oxidative damage 
 All aerobic organisms are susceptible to oxidative stress simply because 
semireduced oxygen species, superoxide and hydrogen peroxide, are produced 
by mitochondria during respiration (Chance et al. 1979). Brain is considered 
abnormally sensitive to oxidative damage (Floyd and Carney 1992). Brain is 
enriched in the more easily peroxidizable fatty acids (20:4 and 22:6), consumes 
an inordinate fraction (20%) of the total oxygen consumption for its relatively 
small weight (2%), and is not particularly enriched in antioxidant defences. In fact, 
brain has lower natural antioxidant glutathione and catalase activity, which is 
about 10% that of liver. Additionally, human brain has higher levels of iron in 
certain regions and in general has high levels of ascorbate. Thus, if tissue 
organizational disruption occurs, the iron /ascorbate mixture is expected to be an 
abnormally potent pro-oxidant for brain membranes (Floyd and Carney 1992; 
Floyd 1999). 
 
4. 2. Iron and neurodegenerative disorders 
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 Abnormally high levels of iron have been demonstrated in a number of 
neurodegenerative disorders such as Parkinson's disease (PD), Alzheimer's 
disease (AD), amyotrophic lateral sclerosis (ALS), prion disease, cataracts and 
mitochondrial disorders (Friedreich's ataxia) (Connor 1992; Qian and Wang 1998; 
Thompson et al 2001; Moos and Morgan 2004; Zecca et al. 2004). Oxidative 
stress resulting from the increased iron levels via Fenton reaction, and possibly 
also from defects in antioxidant defense mechanisms, is widely believed to be 
one of the causes responsible for neuronal death in neurodegenerative diseases 
(Gotz et al. 1994; Dawson and Dawson 1996; Qian et al. 1997; Connor 2003; 
Todorich and Connor 2004), although there is still no general agreement as to 
the causative link between iron-induced oxidative stress and the neuronal death.  
 
4. 2. 1. Parkinson's disease 
 Histopathological, biochemical, and in vivo brain imaging techniques, such 
as MRI and transcranial color-coded real-time sonography, revealed a consistent 
increase of brain iron in PD (Earle 1968; Dexter et al. 1987; Hirsch et al. 1991; 
Gotz et al. 2004). Histochemical iron staining of paraffin sections using Perl's 
stain revealed that in the SN pars compacta, ferric iron was localized in microglia, 
astrocytes often localized next to neurons, and in single nonpigmented neurons, 
and in the rim of Lewy bodies in the substantia nigra pars compacta of patients 
with PD (Jellinger et al. 1990). A similar picture of iron accumulation in glia and 
neurons was found in the putamen and pallidum of the same patients. MRI can 
be used to detect augmented brain iron content in living patients with PD that 
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correlates with measurements from post-mortem tissues (Gorell et al. 1995; 
Ryvlin et al. 1995).  
 Various methods (Jellinger et al. 1993; Zecca et al. 1996) have provided 
compelling evidence for the accumulation of iron in pigmented neurons — in 
particular, in the form of a neuromelanin–iron complex. It was demonstrated that 
synthetic dopamine-derived melanin has a capacity to bind a highly significant 
amount of iron (Ben-Shachar et al. 1991; Double et al. 2003). Neuromelanin 
contains large amount of iron in the SN of patients with PD (Jellinger et al. 1992; 
1993), thus neuromelanin would be rather a neuroprotectant than a neurotoxicant 
in PD brains. It was reported that there is a statistically significant reduction (–
70%) in the number of melanized neurons and an increased nonheme Fe3+ 
content in PD patients, as compared with a group of matched control subjects 
(Faucheux et al. 2003). Consequently, a reduction in iron binding ability of 
neuromelanin would render catecholaminergic neurons more vulnerable due to 
increased redox-capable iron levels (Double et al. 2002; Li et al. 2005). 
 Mutations in α-synuclein cause a form of familial PD. Abnormal 
filamentous aggregates of misfolded α-synuclein protein are the main 
components of Lewy bodies with iron deposits in the rim, perhaps indicating a 
pathogenic role of iron for α-synuclein in PD (Polymeropoulos et al. 1997; Cole et 
al. 2004). In addition, α-synuclein may bind iron, leading to aggregation of α-
synuclein (Kim et al. 2002; Mandel et al. 2004).  
 
4. 2. 2. Alzheimer's disease 
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 Abnormal iron deposition in neuritic plaques can associate with beta-
amyloid (Aβ) and may promote formation of oxygen radicals (Smith et al. 1997; 
Huang et al. 2000; Connor et al. 2001a ; Rottkamp et al. 2001). Iron might also 
have a direct impact on plaque formation through its effects on amyloid precursor 
protein (APP) processing (Mantyh et al. 1993; Rogers et al. 2002; Falangola et al. 
2005). Furthermore, the ability of α-secretase to cleave APP can be modulated 
by iron (Bodovitz et al. 1995).  
 In vitro studies, beta-amyloid binds iron (Garzon-Rodriguez et al. 1999) 
and the bound iron facilitates aggregation(Mantyh et al. 1993; Kuroda and 
Kawahara 1994; ). Also, an in vivo model has been used to show that injection of 
Aβ with iron into rat brain causes more significant damage to neurons than Aβ 
treatment alone (Bishop and Robinson 2000). As a consequence of iron 
accumulation, especially if ferritin does not increase with the increasing iron as 
has been reported in AD and PD (Connor et al. 1995b).  It has been proposed 
that there is a dysfunction in the IRP system in Alzheimer’s disease resulting in 
an increased affinity between the IRP and the binding site on the mRNA (Pinero 
et al. 2000). 
 
4. 2. 3. Other neurological diseases 
 Congenital aceruloplasminaemia — a condition is characterized by 
extrapyramidal symptoms, ataxia and progressive CNS and retinal 
neurodegeneration — mutations in the ceruloplasmin gene cause the protein to 
be absent from the plasma (Yoshida et al. 1995a; Harris et al. 1995). Although 
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this does not affect copper transport, severe iron loading is found in parenchymal 
tissues including the brain, particularly in the basal ganglia. The implications are 
that ceruloplasmin is required for iron mobilization from cells (Harris et al. 1999). 
 Friedreich's ataxia is the most common of the early-onset inherited 
ataxias, and it is characterized by degeneration of the large sensory neurons and 
spinocerebellar tracts, and cardiomyopathy (Patel and Isaya 2001). The disease 
is caused by a substantial reduction in the concentration of the mitochondrial 
protein frataxin, which is provoked by a large GAA triplet-repeat expansion in the 
first intron of the frataxin gene, resulting in a reduction in frataxin expression by 
transcription inhibition (Zoghbi and Orr 2000). This leads to increased 
mitochondrial iron content, which seems to reflect the vital role of frataxin in iron–
sulphur cluster biosynthesis (Gordon 2000; Muhlenhoff et al. 2002; Calabrese et 
al. 2005). Some success has been achieved in retarding the disease-associated 
cardiomyopathy using the ubiquinone analogue 2,3-dimethoxy-5-methyl-6-(10-
hydroxydecyl)-1,4-benzoquinone (Idebenone, Takeda Chemical Industries) 
(Cooper and Schapira 2003). 
 Neuroferritinopathy is a dominantly inherited, late-onset basal-ganglia 
disease, which is caused by a single adenine insertion into the gene for L-chain 
ferritin. This is thought to alter the carboxyl terminus of the protein (Curtis et al. 
2001; Levi et al. 2005). Iron deposition in the basal ganglia, abnormal aggregates 
of ferritin and iron in the globus pallidus and substantia nigra, together with low 
serum ferritin concentrations, are found in affected patients (Crompton et al. 
2002; Mancuso et al. 2005). Patients with neuroferritinopathy had abnormal 
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ferritin accumulation in neurons and glia of the striatum and cerebellar cortex, 
along with severe neuronal loss (Vidal et al. 2004). 
 Hallervorden–Spatz syndrome, an autosomal recessive disease, which 
is characterized by dystonia and pigmentary retinopathy in children and speech 
or neuropsychiatric defects in adults, has a characteristic MRI pattern in the 
globus pallidus, known as 'the eye of the tiger' because of its appearance 
(Hayflick 2003). Mutations in the gene that codes for pantothenate kinase 2 
(PANK2) have been shown to be the main genetic defects associated with 
neurodegeneration with brain iron accumulation (formerly known as 
Hallervorden–Spatz syndrome) (Zhou et al. 2001; Hayflick 2003). Pantothenate 
kinase is necessary for coenzyme-A biosynthesis, and it is targeted to 
mitochondria. It is proposed that accumulation of cysteine, which chelates iron, 
causes oxidative stress and leads to the accumulation of iron in the basal 
ganglia. 
 Restless legs syndrome (RLS) has been identified as a neurological 
disorder in adults that seems to be associated with decreased iron in the 
substantia nigra and a possible defect in IRP1 (Connor et al. 2004). The 
symptoms of RLS are responsive to dopaminergic agonists (Earley 2003).  
 
5.  Animal models of kainic acid induced neuronal injury 
 Kainic acid (KA) is a nondegradable analog of glutmate, and is 30 to 100-
fold more potent than glutamate as a neuronal excitant. Kainate-induced epileptic 
seizure have been widerly used as a model for studying temporal lope epilepsy 
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and neurodegeneration (Sloviter and Dempster 1985; Represa et al. 1990; 
Sutula et al. 1992). A single systemic injection of a convulsive dose of kainate 
results in both short- and long-term effects on the rat central nervous system. 
With 1h of its administration to the rats, the neuronal circuitry of the hippocampus 
is activated and later the animal undergoes robust and recurrent seizures. Within 
3-4 days after kainate injection, pyramidal cells in CA1 and CA3 field of the 
hippocampus begin to degenerate (Coyle et al. 1983; Sutula et al. 1992; Bing et 
al. 1996). 1-2 weeks later, spontaneous convulsions can be observed in kainate-
treated rats. Kainate produces selective degeneration of neurons after 
intraventricular and intracerebral injection, especially in the striatal and 
hippocampal areas of the brain (Lerma 1997; Ben-Ari and Cossart 2000).  Axons 
and nerve terminals are more resistant to the destructive effects of KA than the 
cell soma. 
 An increasing number of studies suggest a cause relation between free 
radicals and excitotoxicity in vivo (Bondy and Lebel 1993; Nakao and Brundin 
1998). Ueda et al. reported direct electron spin resonance (ESR) evidence of 
extracellular free radical formation during KA-induced seizures obtained using in 
vivo brain microdialysis in free moving rats (Ueda et al. 1997). The increased 
concentration of malonaldehyde and 4-hydroxyalkenals, which was measured as 
an index of lipid peroxidation, was found in rat cerebral cortex, cerebellum, 
hippocampus, hypothalamus, and corpus striatum after administration with 
kainate (Melchiorri et al. 1995; Bruce and Baudry 1995), These results strongly 
suggest the involvement of oxygen free radicals in the initial phases of KA-
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induced pathology.  It was found that formation of ROS resulting in alterations in 
the oxidative defense system in the rat hippocampus following KA administration 
(Gilberti and trombetta 2000; Parihar and Hemnani 2004).  A single intra-
peritoneal injection of KA was sufficient to trigger a time-dependent decrease in 
forebrain GSH (maximal reduction at 48 hours), and a good correlation can be 
shown between KA-induced loss of neuron vitality and fall in GSH level (Skaper 
et al. 1999). These findings provide direct in vivo evidence that free radicals are 
involved in KA –induced neuronal injury. 
 Iron can promote oxidative stress, and some recent studies show that 
increased iron, detected by nuclear microscopyic and histochemical methods, is 
observed in rat hippocampus after kainate injection (Ong et al. 1999; Shoham 
and Youdim 2000; Wang et al. 2002b). In the kainate model of epilepsy, it was 
found that iron deprivation protected the olfactory cortex, thalamus and 
hippocampus and attenuated microgliosis, whereas iron supplementation to iron 
deprived rats increased damage and microgliosis in the above regions. Several 
lines of evidence converge to suggest that activation of microglia is an important 
source of oxidative stress. Thus this provided evidence that iron was involved in 
neuronal damage and there is a tight relationship between iron and oxidative 
stress (Shoham and Youdim 2000; 2004).  
6.  The aim of the present study 
 Kainate, an analog of glutamate, can cause neurodegeneration through 
interacting with kainic acid-type receptors in neurons, which induces neuronal 
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Ca2+ overloading. Kainate intracerebroventricular injection in rat brain resulting in 
neurodegeneration is widely used as a model of neurodegeneration. Using this 
animal model, the present study aims to: 
 
1. To elucidate the normal localization of DMT1 in the brain of primates. 
 Immunohistochemistry, Turnbull’s blue stain and electron microscopy 
were carried out to investigate the distribution of DMT1 in monkey basal ganglia 
and any correlation with level of iron.  
 
2. To elucidate the distribution and change of IRPs and DMT1 isoforms 
expression in the rat hippocampus after kainate lesion.  
 This portion of the study was carried out, using immunohistochemistry, 
immunofluorescence, electron microscopy, to investigate the distribution and 
change of IRPs and DMT1 isoforms, and any correlation between IRPs and 
DMT1 isoforms in the rat hippocampus after kainate lesion.  
 
3. To elucidate the distribution and change of ferritin, ferric iron and ferrous iron 
in the rat hippocampus after kainate lesion. 
 This portion of the study was carried out, using immunohistochemistry, 
immunofluorescence, electron microscopy, Perl’s stain and Turnbull’s blue stain , 
to investigate the distribution and change of  ferritin, ferric iron and ferrous iron, 
and any correlation between ferritin and iron in the rat hippocampus after kainate 
lesion.  
 39
 4. To investigate the distribution and change of two iron exporter, ferroportin-1 
and ceruloplasmin, in the hippocampus after kainate injection.  
 This portion of the study was carried out, using immunohistochemistry, 
immunofluorescence, electron microscopy and Western blotting, to investigate 
the distribution and change of ferroportin-1, ceruloplasmin in kainate-induced 
brain injury, and any correlation between iron importer and iron exporter.  
 
5. To elucidate the distribution and change of heme oxygenase-1(HO-1) and its 
product bilirubin expression in the rat hippocampus after kainate lesion. 
 The methods of immunohistochemistry, immunofluorescence and electron 
microscopy were carried out to investigate the distribution and change of HO-1, 



















I. Distribution of Divalent Metal Transporter-1 in the 
Monkey Basal Ganglia 
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1.  Introduction 
Metal ions are important cofactors for a wealth of biological processes, 
including oxidative phosphorylation, gene regulation, and free radical 
homeostasis (Morgan et al. 1996). Iron is also a cofactor for tyrosine hydroxylase 
and tryptophan hydroxylase, which are enzymes involved in synthesis of 
neurotransmitters (Chen et al. 1995). Failure to maintain appropriate levels of 
metal ions in humans is a feature of hereditary hemochromatosis, disorders of 
metal ion deficiency, and certain neurodegenerative diseases (He et al. 1996; 
Qian and Wang 1998; Zoller et al. 1999; Fleming et al. 1999). 
Iron transport into mammalian cells has been shown to occur via a non-
heme iron transporter, divalent metal transporter 1 (DMT1, formerly known as 
DCT-1 or NRAMP2) (Gunshin et al. 1997; Gruenheid et al. 1999). DMT1 
mediates active transport of iron that is proton-coupled, and dependent on the 
cell membrane potential. It is ubiquitously expressed, most notably in the 
proximal duodenum (Gunshin et al. 1997). The transporter has been localized to 
recycling endosomes and the plasma membrane, suggesting that it plays a key 
role in the metabolism of transferrin-bound iron by transporting free Fe2+ across 
the endosomal membrane into the cytoplasm (Gruenheid et al. 1999). Two 
isoforms of DMT1, DMT1a and DMT1b with similar functional characteristics 
have been identified in primates (Zhang et al. 2000). 
The importance of DMT1 in cellular iron transport is seen in patients and 
rodent models of defects in iron transport. An increased expression of DMT1 is 
present in the duodenal mucosa, in patients with hereditary hemochromatosis 
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(Zoller et al. 1999). On the other hand, mutations in DMT1 lead to hypochromic 
microcytic anemia in microcytic anemic (mk/mk) mice and Belgrade rats (Fleming 
et al. 1997, 1998;  Touret et al. 2004). The defect in DMT1 is correlated with 
reduced levels of iron, in the brains of Belgrade rats (Burdo et al. 1999). 
DMT1 mRNA has been detected in cultured sympathetic neurons, granule 
neurons in the dentate gyrus of the hippocampus, and granule and Purkinje 
neurons in the cerebellum (Roth et al. 2000; Williams et al. 2000; Knutson et al. 
2004). The transporter protein has been immunolocalized to astrocytes in the 
striatum, neurons in the thalamus and cerebellum, ependymal cells lining the 
third ventricle, and vascular cells throughout the brain (Burdo et al. 2001). An 
increased DMT1 immunoreactivity, and ferric and ferrous iron, is present in the 
rat hippocampus after kainate-induced neuronal injury (Wang et al. 2002). DMT1 
is present in astrocytic processes and end-feet around blood vessels in the 
monkey cerebral neocortex and hippocampus (Wang et al. 2001).  
Thus far, however, little is known about the distribution of DMT1 in the 
basal ganglia, particularly in primates. The regions in basal ganglia contain high 
iron level, which may correlate to DMT1 expression.  The present study was 
therefore carried out, using immunohistochemistry and electron microscopy, to 
elucidate the distribution of DMT1 in the monkey basal ganglia. The distribution 




2.  Experimental procedures 
2. 1.  Monkeys 
Six adult male or female monkeys (Macaca fascicularis) weighing 3.5 - 4 
kg were used in this study. The ages of the monkeys were estimated from their 
weight, the amount of wear on the dentition by two vets, and were judged to be 
greater than 7 years. The monkeys were deeply anesthetized with an 
intraperitoneal injection of Nembutal (30mg/kg), and transcardially perfused with 
normal saline, followed by a fixative, consisting of 4% paraformaldehyde and 
0.1% glutaraldehyde in 0.1M phosphate buffer (pH 7.4). The brains were 
bisected, and blocks of the left and right basal ganglia removed and post-fixed 
the same fixative overnight. All procedures involving monkeys were in 
accordance with guidelines of the local Animal Care and Use Committee. 
 
2. 2.  Immunohistochemistry 
Blocks containing the basal ganglia were sectioned coronally at 100 µm 
using a vibrating microtome, and free floating sections collected for 
immunostaining. The sections were washed for 3 h in phosphate-buffered saline 
(PBS) to remove traces of fixative, and immersed for 1 h in a solution of 5% 
normal goat serum to block non-specific binding of antibodies. They were then 
incubated overnight with an antibody to DMT1 (Burdo et al. 2001) diluted 1:100 in 
PBS. This antibody was raised against the fourth extracellular domain of DMT1, 
and recognizes both the iron response element- and non-iron response element 
forms of the protein. It has been shown to react against a single band at 62kD, 
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consistent with the expected molecular weight of DMT1, in human tissues (Kishi 
and Tabuchi 1997; Georgieff et al. 2000). The sections were then washed in 
three changes of PBS, and incubated for 1 h at room temperature in a 1:200 
dilution of biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingame, 
U.S.A.). This was followed by three changes of PBS to remove unreacted 
secondary antibody. The sections were then reacted for 1 h at room temperature 
with an avidin-biotinylated horseradish peroxidase complex. The reaction was 
visualized by treatment for 5 minute in 0.05% 3, 3, diaminobenzidine 
tetrahydrochloride (DAB) solution in Tris buffer containing 0.05% hydrogen 
peroxide. The color reaction was stopped with several washes of Tris buffer. 
Some sections were mounted on gelatine-coated glass slides and lightly 
counterstained with methyl green or cresyl fast violet (Nissl stain) before 
coverslipping. The remainder was processed for electron microscopy. Control 
sections were incubated with PBS, pre-immune rabbit serum, or antigen 
absorbed antibody instead of primary antibody. The antigen-absorbed antibody 
was prepared by incubating the 20μg/ml solution of DMT1 immunizing peptide 
with the DMT1 antibody overnight. These sections showed absence of staining 
(Fig. 1. 2F). 
 
2. 3.  Turnbull’s blue histochemical staining for ferrous iron 
This was carried out by following a protocol described previously 
(McManus and Mowry 1960). Sections were washed with distilled water and 
immersed in a potassium ferricyanide mixture (containing 1 part of 2% potassium 
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ferricyanide and 1 part of 2% hydrochloric acid) for 30 minutes, followed by 6 
washes in distilled water at 5 minutes each. Diaminobenzidine enhancement was 
carried out on some of the Turnbull's blue stained sections as described 
previously (Hill and Switzer 1984; Nguyen-Legros et al. 1980). The Turnbull's 
blue stained sections were immersed for 15 min in 0.05% DAB solution in 0.1M 
phosphate buffer (pH 7.4). This was followed by addition of H2O2 to the solution 
(0.5 ml of 1% to 100 ml DAB solution). The sections were immersed in the 
solution for a further 15 minutes, followed by washing in distilled water for 30 
minutes. A few sections were observed using a microscope during the DAB 
reaction, to ensure that only blue cells stained for Turnbull's blue stain were 
converted to brown cells with DAB, i.e. that there were no spurious DAB-labeled 
cells that had not been stained by Turnbull blue's stain. Some of the sections 
were mounted on glass sides, lightly counterstained, dehydrated and 
coverslipped with Permount, and the remainder processed for electron 
microscopy. 
 
2. 4.  Quantification 
Images of DMT1 stained portions of the basal ganglia were captured using 
a Zeiss Axiophot microscope fitted with a video camera, and the density of the 
staining measured using an image analyzing software (Image-Pro Plus, version 
4.1.0.0 for Windows 95/NT/98; Media Cybernatics, Silver Spring, U.S.A.). The 
number of Turnbull's blue stained granules in each portion of the basal ganglia 
was also counted at 200X magnification with the help of a grid. The observer who 
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counted the granules was unaware of the results from the experiments on DMT1. 
Three immunostained or histochemically stained sections from each region of the 
basal ganglia were analysed in each of the monkeys. The results were 
expressed as mean densitometric value or mean number of granules / mm2. The 
results subjected to statistical analysis (1 way ANOVA with Bonferroni’s multiple 
comparison post-hoc test, and linear regression analysis, using SPSS software 
for Windows). p < 0.05 was considered significant for the ANOVA, and p < 0.01 
considered significant for the linear regression analysis. 
 
2. 5.  Electron microscopy 
Electron microscopy was carried out by subdissecting the immunolabeled 
or Turnbull’s blue stained sections into smaller rectangular portions that included 
the caudate nucleus, putamen, globus pallidus externa or interna, subthalamic 
nucleus, and substantia nigra pars compacta or reticulata. These were 
osmicated, dehydrated in an ascending series of ethanol and acetone, and 
embedded in Araldite. Thin sections were obtained from the first 5 µm of the 
sections, mounted on copper grids coated with Formvar, and stained with lead 
citrate. They were viewed using a Philips EM208 electron microscope. 
 
2. 6. Double immunofluorescence labeling 
An additional four adult male or female monkeys were deeply 
anesthetized with an intraperitoneal injection of Nembutal (30mg/kg), and 
transcardially perfused with normal saline, followed by a fixative, consisting of 4% 
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paraformaldehyde in 0.1M phosphate buffer (pH 7.4). The brains were bisected, 
and blocks containing the left or right basal ganglia removed and sectioned 
coronally at 30µm thickness using a freezing microtome. The sections were 
processed for free-floating immunofluorescence staining. They were incubated in 
blocking solution composed of 5% goat serum (Vector) and 0.1% Triton X-100 for 
one hour, followed by incubation with rabbit polyclonal antibody to DMT1 (diluted 
1:100 in PBS) and mouse monoclonal antibody to glial fibrillary acidic protein 
(GFAP, Chemicon, diluted 1µg/ml), a marker for astrocytes, overnight. The 
sections were then washed three times in PBS, and incubated for 1h at room 
temperature in 1:200 dilution of FITC-conjugated goat anti-mouse IgG, and Cy3-
conjugated goat anti-rabbit IgG (both from Chemicon). The sections were 
mounted and examined using an Olympus FluoView FV500 confocal microscopy. 
Control sections were incubated with PBS instead of primary antibodies. These 
showed absence of staining. The numbers of DMT1, GFAP and double-labeled 
cells in each portion of the basal ganglia were then counted. Three sections from 
each region of the basal ganglia were analyzed in each of the four monkeys. The 
mean number / mm2 and the percentage of double-labeled cells in each nuclei 
were then calculated. 
 
3.  Results 
3. 1 Light microscopy 
3. 1. 1 DMT1 staining 
Caudate nucleus and putamen 
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The caudate nucleus (Fig. 1. 1A, B) and putamen (Fig. 1. 1C, D) were 
densely stained for DMT1. Dense staining was observed in the neuropil, and 
processes were often seen forming end-feet around blood vessels (Fig. 1. 1B, 
D). These processes were found to be astrocytic processes at electron 
microscopy (see below). In contrast to the dense staining of processes, light or 
no staining was observed on cell bodies. 
 
Globus pallidus externa and interna 
The globus pallidus externa and interna, as a whole appeared more lightly 
stained than the caudate nucleus and putamen (Fig. 1. 1C, E). This was due to 
the large number of axons that passed through these structures. The neuropil 
between the fibre bundles, however, contained labeled astrocytic end feet around 
blood vessels (Fig. 1. 1E). These were found to be astrocytic processes at 
electron microscopy (see below). 
 
Subthalamic nucleus 
The subthalamic nucleus was lightly stained for DMT1 (Fig. 1. 2A, B). 
Light labeling was observed in neuronal cell bodies. The neuropil was also lightly 
stained, and contained relatively few processes (Fig. 1. 2A, B). A similar pattern 
of staining was also observed in most regions of the thalamus (data not shown). 
 
Substantia nigra pars compacta 
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As in the subthalamic nucleus, light staining was observed in neuronal cell 
bodies and the neuropil, in the substantia nigra pars compacta (Fig. 1. 2C, D). 
 
Substantia nigra pars reticulata 
The substantia nigra pars reticula differed from the substantia nigra pars 
compacta, but resembled the caudate nucleus and putamen, in that, little or no 
staining was observed in cell bodies, but dense staining was observed in the 
neuropil (Fig. 1. 2C, E). Control sections incubated with antigen-absorbed 
antibody showed absence of staining (Fig. 1. 2F). 
Sections of the substantia nigra that had been immunostained with DMT1 
and counterstained with Nissl stain, showed dense DMT1 staining over the 
substantia nigra pars reticulata, but light DMT1 staining in the region of large 
neurons containing abundant Nissl substance and typical of substantia nigra pars 
compacta (Fig. 1. 3A). Staining was particularly intense at the border zone 
between the substantia nigra pars reticulata and the cerebral peduncles, but the 
cerebral peduncles themselves were not labeled (Fig. 1. 3A). 
 
3. 1. 2. Turnbull’s blue histochemical staining for ferrous iron 
The densest staining was observed in the substantia nigra pars reticulata 
(Fig. 1. 3B, C) and the globus pallidus externa and interna, followed by the 
caudate nucleus (Fig. 1. 3D) and putamen (Fig. 1. 3E). Few granules were 
observed in the substantia nigra pars compacta. In non-counterstained sections, 
the brown neuromelanin-rich dopaminergic neurons in the substantia nigra pars 
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compacta were found to be separated from the ferrous iron granules in the 
substantia nigra pars reticulata (Fig. 1. 3B, C). 
 
3. 2. Comparison between DMT1 staining and ferrous iron staining 
The staining intensity for DMT1 and the number of ferrous iron granules in 
different regions of the basal ganglia are shown in Table 1.1. In general, regions 
that stained densely for DMT1 were also those that contained large numbers of 
ferrous iron granules. For instance, the substantia nigra pars reticulata contained 
significantly denser DMT1 staining, and also observed to contain significantly 
greater number of ferrous iron granules, than the substantia nigra pars compacta 
(p < 0.05 in both cases). The exceptions were the globus pallidus externa and 
interna, where light DMT1 staining, but large numbers of ferrous iron granules 
were observed (Table 1. 1). When these were excluded from analysis, a 
significant correlation was observed between the intensity of DMT1 staining and 
number of ferrous iron granules in the different nuclei, by linear correlation 
analysis (R2=0.8708, p <0.01, Fig. 1. 4). 
 
3. 3 Electron microscopy 
The caudate nucleus and putamen contained unlabeled neuronal cell 
bodies, but large numbers of labeled processes in the neuropil (Fig. 1. 5A). Some 
of the labeled processes were observed to form end feet around blood vessels 
(Fig. 1. 5B). Light labeling was also observed in astrocytic cell bodies. The 
substantia nigra pars reticulata showed a similar pattern of staining as the 
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caudate nucleus and putamen. Dense staining was observed in astrocytic end 
feet around blood vessels, but light staining was observed in astrocytic cell 
bodies (Fig. 1. 5C). 
The ultrastructural features of the iron granules observed in the substantia 
nigra pars reticulata were also examined. These granules were found to be 
present in cells with features of oligodendrocytes. The latter had regular 
cytoplasmic outlines, an eccentrically placed nucleus within the cell body, dense 
heterochromatin clumps in the nucleus, and absence of dense bundles of glial 
filaments characteristic of astrocytes (Fig. 1. 6). The iron rich granules were 
present in the cytoplasm on one side of the nucleus (Fig. 1. 6). 
 
3. 4. Double immunofluorescence labeling for DMT1 and GFAP (Fig. 1. 7. Table  
1. 2 ) 
The caudate nucleus was densely labeled for both GFAP and DMT1. 
DMT1 labeling was observed denser in processes than in cell bodies. Many of 
the processes were double labeled for GFAP, indicating that they were astrocytic 
processes (Fig. 1. 7A). The putamen showed a similar pattern of staining as the 
caudate nucleus (data not shown). The globus pallidus contained light astrocytic 
DMT1 labeling (data not shown) as in the peroxidase stained sections. Other 
regions also contained astrocytic DMT1 staining except subthalamic nucleus and 
the substantia nigra pars compacta (Table 1.2). The subthalamic nucleus (Fig. 1. 
7B) and the substantia nigra pars compacta (Fig. 1. 7C) contained DMT1 
positive, presumably neuronal cell bodies, which were not labeled for GFAP 
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(Table 1.2). The substantia nigra pars reticulata, in contrast, showed a pattern of 
staining that was similar to the caudate nucleus and putamen, i.e. it contained 
many DMT1 and GFAP double labeled, astrocytic processes (Fig. 1. 7D).  
 
4. Discussion 
The present study aimed to elucidate the distribution of DMT1 in the 
normal monkey brain. High levels of DMT1 were observed in the caudate 
nucleus, putamen, and the substantia nigra pars reticulata. In contrast, the 
globus pallidus was lightly stained for DMT1. Light staining was also observed in 
neurons, in the thalamus, subthalamic nucleus, and the substantia nigra pars 
compacta. 
The high level of staining in the caudate nucleus, putamen and substantia 
nigra pars reticulata was due to the large number of DMT1 positive astrocytic 
processes, including astrocytic end-feet in these nuclei. The proximity of 
astrocytic end free to blood vessels suggests an essential role of astrocytes in 
the transport of iron across the blood brain barrier in these regions. The main 
mode of iron across the blood brain barrier appears to be receptor-mediated 
endocytosis of iron-containing transferrin by capillary endothelial cells (reviewed 
in Moos and Morgan 2000), but in view of the location of DMT1 on the astrocytic 
end feet around blood vessels, it has been postulated that DMT1 could play a 
role in the transport of iron into the brain (Wang et al. 2001). The localization of 
DMT1 in astrocytic processes and end feet is consistent with previous 
observation of DMT1 localisation in the normal rat and monkey cerebral 
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neocortex and hippocampus (Wang et al. 2001). A previous study on the rat 
brain has also shown DMT1 staining in astrocytes in the striatum, but light 
staining in neurons of the thalamus (Burdo et al. 2001). A recent study has also 
shown that DMT1 and metal transport protein are localized in astrocytes in vitro 
(Jeong and David 2003). 
The possibility that astrocytic DMT1 is an important factor in iron 
accumulation in the basal ganglia is supported by the observation that, in 
general, regions of the brain that were densely stained for DMT1 were also 
regions that were densely stained for ferrous iron granules. Thus, regions such 
as the caudate nucleus, putamen, and substantia nigra pars reticulata contained 
dense staining of DMT1 in astrocytic processes, and were also observed to 
contain large numbers of ferrous iron granules. An exception was the globus 
pallidus externa and interna, which contained light DMT1 staining, but large 
numbers of ferrous iron granules. The reason for this difference is not known. A 
similar mismatch between TfR densities and iron levels in the globus pallidus has 
been reported in the human brain. TfR density is high in the neocortex, moderate 
in the putamen and caudate nuclei but very low in the globus pallidus and 
substantia nigra (Griffiths et al. 1996). The accumulation of iron in the globus 
pallidus therefore appears to be due to factors other than iron transport across 
the blood brain barrier. A pathological increase in iron levels in these nuclei 
occurs in Hallervorden-Spatz syndrome, and it has been reported that an 
enzymatic block in the metabolic pathway from cysteine to taurine may result in 
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accumulation of cysteine which has ability to chelate iron, in the globus pallidus 
(Perry et al. 1985; reviewed in Ke and Qian 2003). 
It is known from human post-mortem studies that a higher level of iron 
exists in the substantia nigra pars reticulata, compared to the substantia nigra 
pars compacta (Jellinger et al. 1990; Sofic et al. 1991). A high level of iron has 
also been demonstrated in the substantia nigra pars reticulata, in normal subjects 
using MRI (Bartzokis et al. 1999). A recent study using the technique of nuclear 
microscopy to accurately measure and map elemental iron in hemiparkinsonian 
monkeys, has confirmed that iron granules are located in the substantia nigra 
pars reticulata, and not the pars compacta, of monkeys greater than 7 years of 
age (Ren et al. 2003). It is postulated that the high levels of ferrous iron could 
affect the function of the neurons in the pars reticulata. The maximal release of 
[3H] GABA evoked by NMDA under K+ depolarization has been shown to be 
significantly higher in retinal cells treated with iron / ascorbate, compared with 
controls (Agostinho et al. 1996). It is possible that high levels of extracellular iron 
could similarly affect NMDA receptors on substantia nigra reticulata neurons in 
human patients with Parkinson’s disease, leading to increased GABA release 
from these neurons and increased inhibition of the thalamus and cortex as a 
result. The iron content of the substantia nigra pars compacta has been shown to 
increase in patients with Parkinson’s disease (Jellinger et al. 1990; Sofic et al. 
1991). It is possible that this could occur as a consequence of cell death, since 
our recent studies showed an increased expression of DMT1 and iron the 
degenerating hippocampus after kainate induced neurodegeneration (Ong et al. 
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1999; Wang et al. 2002). Further work is necessary to elucidate the expression 










II. Upregulation of Iron Regulatory Proteins and Divalent 
Metal Transporter-1 Isoforms in the Rat Hippocampus 




Iron participates in a variety of metabolic processes including oxygen 
transport, electron transport and DNA synthesis, and is essential for the proper 
functioning of the nervous system. On the other hand, excess iron could catalyze 
the formation of free radicals through the Haber Weiss or Fenton reactions, and 
may be a source of damage to cells. Increases in iron have been detected in the 
substantia nigra of Parkinson’s disease and amyloid plaques in Alzheimer’s 
disease (AD), and it is increasingly recognized that changes in brain iron 
metabolism could be a pathogenic co-factor in these diseases (Rouault 2001; Ke 
and Qian 2003). Iron influx into the brain occurs through binding of serum iron-
transferrin complexes to transferrin receptor-1 (TfR1) on brain endothelial cells, 
followed by endocytosis, dissociation of iron from transferrin, and recycling of 
apo-transferrin to the blood (Reviewed in Moos and Morgan 2000). Transcytosis 
of iron-transferrin complexes could also occur across the endothelial cells. In 
addition, the DMT1 is thought to play a role in brain iron influx (Burdo et al. 1999, 
Wang et al. 2003). The iron storage protein, ferritin, sequesters excess iron, 
preventing it from catalyzing the formation of free radicals. 
 The expression of the above proteins is affected by iron regulatory 
proteins (IRPs). These include IRP1 and IRP2, which bind to stem-loop 
structures on specific mRNAs, known as iron-responsive elements (IREs) (Kuhn 
and Hentz 1992; Kim et al. 1995; reviewed in Eisenstein 2000). In iron-deficient 
cells, binding of IRPs to IREs on the 3' untranslated regions (UTRs) of TfR1 
mRNA results in stabilization of the mRNA and increased TfR translation. On the 
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other hand, binding of IRPs to the 5' UTR of ferritin mRNA prevents ferritin 
translation. These actions of IRP lead to increased iron uptake by TfR1, but 
decreased iron sequestration in ferritin stores, in iron-deficient cells. In iron-
replete cells, IRPs detach from IREs, resulting in decreased TfR-1, but increased 
ferritin expression (Reviewed in Pantopoulos 2004). IRP1 is regulated by an iron-
sulfur cluster switch (Haile et al. 1992). The latter disassembles and apo-IRP1 
acquires IRE binding activity in iron deficient cells, but assembles into a cluster 
which inhibits its IRE-binding activity, in iron-replete cells. This cluster also 
converts IRP1 into a cytosolic aconitase. IRP2 is synthesized under conditions of 
iron starvation (Henderson and Kuhn 1995; Popovic et al. 2005), remains stable 
in iron-starved and hypoxic cells (Hanson et al. 1999), and undergoes 
proteasomal degradation in iron replete and normoxic cells (Guo et al. 1995). 
An increase in iron staining has been reported in the rat globus pallidus 
after injection of the excitotoxins kainate or quinolinate to the ventral striatum 
(Shoham et al. 1992). Increases in iron staining and levels were also detected in 
the substantia nigra after injections of ibotenate to the striatum or globus pallidus 
(Sastry and Arendash 1995). Our previous study showed a progressive increase 
in iron concentration in the rat hippocampus after intracerebroventricular kainate 
injections, using the technique of nuclear microscopy (Ong et al. 1999). Since the 
latter measures elemental levels regardless of their chemical state, the findings 
indicate increased uptake, and not just redistribution of iron. Upregulation of 
DMT1 was observed in the degenerating hippocampus after kainate injections 
(Wang et al. 2002a). Since some isoforms of DMT1 contain an IRE (Gunshin et 
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al. 1997; Hubert and Hentze 2002; Lee et al. 1998), one possibility is that 
changes in IRP expression after kainate injury could have caused an increase in 
DMT1 expression and iron influx into the brain. The present study was therefore 
carried out, to investigate the distribution and change of IRPs and DMT1 
isoforms, and any correlation between IRPs and DMT1 isoforms in the rat 
hippocampus after kainate lesion.  
 
2. Materials and methods 
2. 1. Antibodies 
Affinity-purified rabbit polyclonal antibodies to IRP1 or IRP2 were 
purchased from Alpha Diagnostic International (San Antonio, USA). The 
antibodies were raised against a 20-aa peptide sequence within the N-terminus 
of rat IRP1, or a 20-aa peptide sequence in the N-terminus of rat /mouse/human 
IRP2 respectively. Affinity purified rabbit polyclonal antibodies to DMT1 (+IRE 
and –IRE) and -IRE DMT1 were custom made in the laboratory of Dr. Connor. 
The antibody to DMT1 was raised against the sequence of the third extracellular 
loop of DMT1 in rabbit, and recognizes both the iron response element 
containing (+IRE) and non-iron response element (-IRE) forms of the protein 
(Burdo et al. 1999). The antibody to the non-IRE form of DMT1 (-IRE DMT1) was 
raised against the C terminus of DMT1 and recognizes only the -IRE form of the 
transporter. 
  
2. 2. Animals and kainate injection 
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 Male Wistar rats of approximately 200g each were used. They were 
anaesthetized by intraperitoneal injection of 1.2 ml of 7% chloral hydrate, and the 
cranial vault exposed. Kainate (1 µl of a 1 mg/ml solution in saline) was injected 
into the right lateral ventricle (coordinates: 1.0 mm caudal to bregma, 1.5 mm 
lateral to the midline, 4.5 mm from the surface of the cortex) using a microlitre 
syringe. The needle was withdrawn 10 min later, and the scalp sutured. The 
kainate injections resulted in seizures in the rats, after they had recovered from 
the anesthesia. Control rats were injected with 1 µl of physiological saline, 
instead of kainate. The kainate or saline injected were sacrificed at various time 
intervals after injection for Western blot or immunohistochemical analyses. All 
procedures involving animals were in accordance with guidelines of the local 
Animal Care and Use Committee. 
 
2. 3. Western blot analysis 
 Three 1-week post-kainate injected rats and three 1 week post-saline 
injected rats were used for this portion of the study. They were deeply 
anesthetized with an intraperitoneal injection 1.5 ml of 7% chloral hydrate, and 
decapitated. The right hippocampus was removed and homogenized in 10 
volumes of ice-cold lysis buffer (150 mM sodium chloride, 50 mM Tris 
hydrochloride, 0.25 mM EDTA, 1 % Triton X-100, 0.1% sodium orthovanadate, 
and 0.1% protease inhibitor cocktail, pH 7.4). After centrifugation at 1,000 g for 
15 min at 4oC, the supernatant was collected. The protein concentrations in the 
preparation were then measured using the Bio-Rad protein assay kit. The 
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homogenates (40 μg) were resolved in 10% SDS-polyacrylamide gels under 
reducing conditions and electrotransferred to a polyvinylidene difluoride (PVDF) 
membrane. Nonspecific binding sites on the PVDF membrane were blocked by 
incubation with 5% non-fat milk in 0.1% Tween-20 TBS (TTBS) for 1 hr. The 
PVDF membrane was then incubated overnight in polyclonal antibody to IRP1 
(1:250), IRP2 (1:250), DMT1 (+ IRE and - IRE, 1:1000) or -IRE DMT1 (1:500) in 
1% bovine serum albumin in TTBS. After washing with TTBS, the membrane was 
incubated with horseradish peroxidase-conjugated goat anti-rabbit IgG (1:5,000 
in TTBS, Pierce, Rockford, IL) for 1 hr at room temperature. Immunoreactivity 
was visualized using a chemiluminescent substrate (Supersignal West Pico, 
Pierce, Rockford, IL). Loading controls were carried out by incubating the blots at 
50°C for 30 min with stripping buffer (100 mM 2-mercaptoethanol, 2% SDS, and 
62.5 mM Tris-hydrochloride, pH 6.7), followed by reprobing with a mouse 
monoclonal antibody to β-actin (Sigma; diluted 1:5,000 in TTBS) and horseradish 
peroxidase conjugated anti-mouse IgG (1:5,000 in TTBS, Pierce). Exposed films 
containing blots were scanned and the densities of the bands measured, using 
Quantity One Version 4 software (Bio-Rad, Hercules, CA). The densities of the 
IRP1, IRP2, DMT1 (+IRE and -IRE) and -IRE DMT1 bands were normalized 
against those of β-actin, and the mean ratios calculated. Possible significant 
differences between the values from the kainate- or saline injected hippocampus 




2. 4. Immunohistochemistry 
Twenty-four rats were used for this portion of the study, of which 20 were 
injected with kainate and 4 were injected with saline. The kainate-injected rats 
were killed at 3 days, 1 week, 2 weeks, 4 weeks and 8 weeks after injection (4 
kainate-injected rats at each postinjection time interval). The saline injected rats 
were sacrificed at 4 weeks postinjection. The rats were deeply anesthetized by 
intraperitoneal injection of 1.5 ml 7% chloral hydrate, and perfused through the 
left ventricle with a solution of 4% paraformaldehyde and 0.1% glutaraldehyde in 
0.1 M phosphate buffer (pH 7.4). The brains were dissected out, and blocks 
containing the dorsal hippocampus sectioned coronally at 100 µm using a 
vibrating microtome, and free floating sections collected. The sections were 
divided into sets. The first was mounted on gelatinized slides and stained with 
cresyl fast violet (Nissl stain). The remaining sections were washed for 3 hr in 
phosphate buffered saline (PBS) to remove traces of fixative, and immersed for 1 
hr in a solution of 5% normal goat serum to block non-specific binding of 
antibodies. They were then incubated overnight with rabbit polyclonal antibodies 
to IRP1 (1:100), IRP2 (1:200), DMT1 (+ IRE and - IRE, 1:100) or -IRE DMT1 
(1:100), The sections were then washed in three changes of PBS, and incubated 
for 1 hr at room temperature in a 1:200 dilution of biotinylated goat anti-rabbit IgG 
(Vector Laboratories, Burlingame, USA). This was followed by three changes of 
PBS to remove unreacted secondary antibody. The sections were then reacted 
for 1 hr at room temperature with an avidin-biotinylated horseradish peroxidase 
complex. The reaction was visualized by treatment for 5 minute in 0.05% 3, 3,-
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diaminobenzidine tetrahydrochloride (DAB) solution in Tris buffered saline 
containing 0.05% hydrogen peroxide. The color reaction was stopped with 
several washes of Tris buffer. Some sections were mounted on gelatin-coated 
glass slides and lightly counterstained with methyl green before coverslipping. 
The remainder was processed for electron microscopy. Control sections were 
incubated with PBS, pre-immune rabbit serum, or antigen absorbed antibody 
instead of primary antibody. The antigen-absorbed antibodies were prepared by 
incubating a 50 µg/ml solution of DMT1(+IRE and –IRE), -IRE DMT1, IRP1 or 
IRP2 immunizing peptide with the IRP1, IRP2, DMT1(+IRE and –IRE) or -IRE 
DMT1 antibodies overnight. These showed absence of immunostaining. 
 
2. 5 Electron microscopy 
 This was carried out as described in Chapter II, I. 2. 5 (Page 52). 
 
2. 6 Double immunofluorescence labeling 
 Four 2 week post-kainate injected rats and four 8 week post-kainate 
injected rats were used for this portion of the study. The rats were deeply 
anesthetized by intraperitoneal injection of 1.5 ml 7% chloral hydrate, and 
transcardially perfused with normal saline, followed by a fixative, consisting of 4% 
paraformaldehyde in 0.1M phosphate buffer (pH 7.4). The brains were dissected 
out, and blocks containing the dorsal hippocampus sectioned coronally at 40 µm 
using a freezing microtome. The sections were processed for free-floating double 
immunofluorescence labeling. Sections were washed for 3 hr in phosphate-
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buffered saline containing 0.1% Triton (PBS-Tx) to remove traces of fixative, and 
immersed for 1 hr in a solution of 5% normal goat serum in PBS-Tx to block non-
specific binding of antibodies. They were then incubated overnight with rabbit 
polyclonal antibodies to IRP1 (1:100), IRP2 (1:200), DMT1 (+ IRE and - IRE, 
1:100) or -IRE DMT1 (1:100) and mouse monoclonal antibody to glial fibrillary 
acidic protein (GFAP, Chemicon, Temecula, USA, diluted 1:1000) or OX42 
(Serotec, Oxford, UK, diluted 1:100). The sections were then washed three times 
in PBS, and incubated for 1hr at room temperature in 1:200 dilution of FITC-
conjugated goat anti-mouse IgG, and Cy3-conjugated goat anti-rabbit IgG (both 
from Chemicon). They were mounted and examined using an Olympus FluoView 
FV500 confocal microscopy. Control sections were incubated with pre-immune 
rabbit or mouse serum instead of primary antibodies. These showed absence of 
staining. 
 
2. 7. Cell counts 
The number of IRP1 / IRP2 /DMT1(+IRE and –IRE) / -IRE DMT1 stained 
cells in representative regions of field CA1 of the hippocampus of each rat was 
counted in a "blind" manner on coded slides. Three immunostained sections from 
each of the four rats in each category were counted, and the results were 
expressed as mean number of stained cells / mm2. The results were subjected to 
statistical analysis using 1-way ANOVA with Bonferroni's multiple comparison 




3. 1. Western blot analyses of IRP and DMT1 expression after kainate lesions 
(Fig. 2. 1, 2) 
 The antibodies to IRP1, IRP2, detected main bands at 98 kDa and 100 
kDa, consistent with the expected molecular weights of the respective proteins 
(Leibold et al. 2001). The antibody to DMT1(+IRE and –IRE) detected a major 
band at 50k Da and a minor band at 60 kDa, whilst the antibody to –IRE DMT1 
detected a major band at 60 kDa, consistent with other reports (Roth et al. 2000; 
Lis et al. 2003). The antibody to beta-actin reacted against a band at 42 kDa. 
Significant increases in density ratios of IRP1, IRP2, DMT1(+IRE and –IRE) or -
IRE DMT1 to beta-actin bands were observed in Western blots of the 1-week 
post-kainate-injected rats, compared to saline-injected rats (p < 0.05; Fig. 2. 2). 
 
3. 2. Immunohistochemical analyses of IRP and DMT1 expression after kainate 
lesions 
3. 2. 1.  Light microscopy 
Saline injected rats (Table 2. 1, Fig. 2. 3) 
 Little or no IRP1 (Fig. 2. 3A), IRP2 (Fig. 2. 3B) or -IRE DMT1 (Fig. 2. 3D) 
immunoreactivity was observed in the hippocampus of saline injected rats. 
Occasional glial cells with morphological features of astrocytes and glial end-feet 
were labeled with the antibody DMT1(+IRE and –IRE) that recognizes both 
DMT1 isoforms (Fig. 2. 3C). 
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Kainate lesioned rats 
Three days after kainate injection (Table 2. 1, Fig. 2. 3) 
Loss of neurons was observed in fields CA1 and CA3 of the hippocampus, 
in Nissl stained sections (data not shown). No significant change in number of 
IRP1 immunopositive cells was observed compared to the unlesioned 
hippocampus, at this time (Fig. 2. 3E). In contrast, a small increase in number of 
IRP2 (Fig. 2. 3F), DMT1 DMT1(+IRE and –IRE) (Fig. 2. 3G) or -IRE DMT1 (Fig. 
2. 3H) positive glial cells was observed in the lesioned CA1/ CA3 fields, 
compared to the control hippocampus (Table 2. 1). 
 
One to four weeks after kainate injection (Table 2. 1, Fig. 2. 4)  
Loss of neurons, and large numbers of glial cells were observed in fields 
CA1 and CA3 of the hippocampus, in Nissl stained sections at these times (data 
not shown). A significant increase in IRP1 (Fig. 2. 4A), IRP2 (Fig. 2. 4B), DMT1 
DMT1(+IRE and –IRE) (Fig. 2. 4C) or -IRE DMT1 (Fig. 2. 4D, Table 2. 1) labeling 
was observed in the degenerating CA fields at these times, compared to the 
unlesioned hippocampus. The numbers of IRP1, IRP2, DMT1 DMT1(+IRE and –
IRE) or -IRE DMT1 positive glial cells peaked at 2 weeks post-kainate injected 
rats (625 + 129, 1188 + 149, 1466 + 195, 700 + 122 cells / mm2 respectively) 
(Table 2. 1). 
The number of IRP2 positive glial cells was significantly greater than that 
of IRP1 (p < 0.05). The number of DMT1(+IRE and –IRE) positive glial cells was 
also significantly greater than that of -IRE DMT1 (P < 0.05).  
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IRP1, IRP2, DMT1 or -IRE DMT1 immunoreactivity was mostly observed 
in a population of glial cells with large diameter processes that tapered gradually 
from the cell bodies, characteristic of astrocytes. 
 
Eight weeks after kainate injections (Table 2. 1, Fig. 2. 4) 
A dense glial scar was observed in the degenerating CA1 and CA3 fields, 
in Nissl sections (data not shown). Large numbers of IRP1 (Fig. 2. 4E), IRP2 
(Fig. 2. 4F), DMT1(+IRE and –IRE) (Fig. 2. 4G) or -IRE DMT1 (Fig. 2. 4H) 
positive glial cells were still observed the degenerating CA fields, and no 
significant differences in numbers of IRP1, IRP2, DMT1(+IRE and –IRE) or -IRE 
DMT1 positive glial cells were detected between the 8 week postinjected 
hippocampus (487 + 83, 907 + 109, 975 + 96, 525 + 86, cells / mm2, 
respectively), and the 4 week postinjected hippocampus (575 + 86,1125 + 170, 
1204 + 144, 579 + 116 cells / mm2, respectively). 
 
3. 2. 2. Electron microscopy (Fig. 2. 5) 
 Large numbers of IRP1, IRP2, DMT1(+IRE and –IRE) or -IRE DMT1 
positive glial cells were found in the degenerating CA1 and CA3 fields of rats that 
had been injected with kainate 2 weeks previously. Most of the IRP1 (Fig. 2. 5A), 
IRP2 (Fig. 2. 5B), DMT1(+IRE and –IRE) (Fig. 2. 5C) or -IRE DMT1 (Fig. 2. 5D) 
positive glial cells had large cell bodies with irregular cell outlines. The nucleus 
contained evenly dispersed fine heterochromatin clumps, and absence of 
marginated heterochromatin on the inner aspect of the nuclear envelope. The 
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cytoplasm contained dense bundles of glial filaments. They thus had features of 
astrocytes. 
 
3. 2. 3 Double immunofluorescence labeling (Fig. 2. 6, Table 2. 2) 
 Dense staining for IRP1, IRP2, DMT1 or -IRE DMT1 was observed in glial 
cells, in the 2 weeks post-kainate injected rats. The IRP1 (Fig. 2. 6A-C), IRP2 
(Fig. 2. 6D-F), DMT1(+IRE and –IRE) (Fig. 2. 6G-I) or -IRE DMT1 (Fig. 2. 6J-L) 
positive glial cells had large diameter processes that tapered gradually from the 
cell bodies, and were mostly (89.2 + 6.4%, 91.6 + 1.5%, 92 + 0.9% and 88.7 + 
4.2%) double labeled for GFAP, indicating these were astrocytes. A small 
proportion of IRP1 (10.2 + 7.6%) or -IRE DMT1 (10.1 + 3.3%) positive glial cells 
were doubled labeled for OX42, indicating that they were microglia. 
 
4. Discussion 
The present study was carried out to elucidate the expression of iron 
regulatory proteins (IRP 1 or IRP2) and iron responsive element (+IRE) - or non-
IRE forms of DMT1 (DMT1 or -IRE DMT1) in the hippocampus after neuronal 
injury induced by kainate. An increase in IRP1, IRP2, DMT1(+IRE and –IRE) and 
-IRE DMT1 protein was observed in the hippocampus after kainate lesions, as 
shown by Western blot and immunohistochemical analyses. Double 
immunofluorescence labeling showed that IRP1, IRP2, DMT1(+IRE and –IRE) 
and -IRE DMT1 were mostly expressed in GFAP positive astrocytes. The number 
of IRP2 or DMT1(+IRE and –IRE) positive glial cells were significantly greater 
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that of IRP1 or -IRE DMT1 positive glial cells respectively. Non-specific staining 
by the IRP1, IRP2, DMT1(+IRE and –IRE) or -IRE DMT1 antibodies is unlikely, 
since well-characterized antibodies were used. Sections that had been incubated 
with antigen-preabsorbed antibody also showed absence of staining (inset in Fig. 
2. 4B, D). 
The observation of IRP1 and IRP2 staining in GFAP positive astrocytes is 
consistent with the results of a previous study which showed astrocytic 
expression of these two regulatory proteins in the perinatal rat brain (Siddappa et 
al. 2002). The number of IRP2 immunolabeled glial cells was, however, greater 
than that of IRP1 in the kainate lesioned CA1 / CA3. This finding is similar to the 
results of previous studies on cultured cells, which showed increased IRP2 but 
not IRP1 activity after hypoxia (Hanson et al. 1999). It has been reported that 
IRP2 dominates the post-transcriptional regulation of iron in mammals (Meyron-
Holtz et al. 2004; Galy et al. 2005; Cooperman et al. 2005). 
  The observation of DMT1 expression in GFAP positive astrocytes is 
consistent with previous observations of DMT1 localization in vitro (Jeong and 
David 2003), and in the normal (Burdo et al. 2001) and kainate lesioned rat 
hippocampus in vivo (Wang et al. 2003). In this study we attempted to distinguish 
between the IRE and the non-IRE form of DMT1 using an antibody that 
recognizes both isoforms, and one that only recognizes the non-IRE form. The 
latter was directed against a unique 25 amino acid segment of the C terminus of 
the -IRE DMT1 (Roth et al. 2000). Comparison of the number of DMT1 (+IRE and 
-IRE) and the -IRE DMT1 showed that there was a significant difference in the 
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number of glial cells that were labeled with these two antibodies. This result 
implies that there were significant numbers of DMT1 (+IRE and –IRE) positive 
glial cells that did not contain the non-IRE isoform of DMT1, i.e. presumably 
contain the + IRE isoform, suggesting that both these isoforms could be 
important in causing a disregulation of iron in the hippocampus after kainate 
lesions (Ong et al. 1999). 
The increase in +IRE DMT1 after kainate injury suggests that the increase 
could be driven by IRPs. In contrast to IRP1, which could function either as an 
IRP by binding to IRE, or a cytoplasmic aconitase, IRP2 has no other function, 
and an increased expression of IRP2 likely implies an increase in IRE binding 
activity due to this isoform. A close correlation between IRP- and DMT1 
expression has also been observed in astrocytic processes in the perinatal rat 
brain (Siddappa et al. 2002), at a time when there is increased iron staining in 
certain regions of the brain (Connor et al. 1995). These observations suggest 
that IRPs plays a role in increased expression of the IRE form of DMT1. 
Nevertheless, it should be noted that in mouse fibroblasts DMT1 mRNA was not 
regulated by iron, even through IRP activity levels changed markedly (Wardrop 
and Richardson 1999). The regulation of DMT1 by IRPs may therefore be cell-
specific, and further work is necessary to clarify this issue in neural cells. 
In any case, the increased expression of -IRE DMT1 after kainate injury 
indicates that IRP is unlikely to be only factor determining the expression of 
DMT1. One possibility, in view of previous observations that the promoter region 
of the human DMT1 gene contains putative AP-1 and NF-(B binding sites, a 
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possible γ-interferon responsive element, and a Hif-1-like motif (Kishi and 
Tabuchi 1998; Lee et al. 1998), is that increased NF-(B or AP-1 expression in the 
degenerating hippocampus (Pennypacker et al. 1994) could result in activation of 
the DMT1 promoter, leading to increased DMT1 expression. Both, +IRE and -IRE 
forms of DMT1, were upregulated in mouse macrophages after treatment with 
pro-inflammatory mediators (Wardrop et al. 2002; Wang et al. 2005). Mice that 
overexpress the pro-inflammatory cytokine, interleukin-6, also showed increased 
iron deposition in the brain (Castelnau et al. 1998). In contrast, daily injections of 
quinacrine, which blocks AP-1 binding to DNA (Stuhlmeier 2001), resulted in 
modulation of DMT1 expression and iron accumulation in the hippocampus after 
kainate injections (Wang et al. 2003). Collective evidence therefore suggests that 
changes in AP-1, NF-(B or other transcription factors could cause brain iron 
accumulation by affecting the expression of DMT1. 
Only a minority of IRP1 or IRP2 positive cells were found to be double 
labeled for OX42, a marker for microglia, in the present study. This observation is 
consistent with our observations of increased ferritin expression in many of these 
cells after kainate lesions. Low levels of IRP may facilitate unbinding of the 
regulatory protein from ferritin mRNA, thus facilitating translation of this protein 
(Pantopoulos 2004). 
A role of iron in pathogenesis of kainate injury has been demonstrated, 
when it was found that rats fed with an iron deficient diet showed reduced 
microgliosis and neuronal loss in the hippocampus, after kainate lesions 
(Shoham and Youdim 2000; 2004). Our own studies showed progressively 
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increased lipid peroxidation in the hippocampus after kainate lesions, as detected 
by levels of F2 isoprostanes (Ong et al. unpublished observations). These 
findings parallel our earlier observations of increased amounts of both ferric and 
ferrous forms of iron in the degenerating hippocampus after kainate lesions (Ong 
et al. 1999; Wang et al. 2002b), and suggest that the increased iron in the 
hippocampus could be a source of free radicals, which might contribute to 
neuronal injury at long time intervals after the initial excitotoxic insult caused by 
kainate. 
There is a general similarity between the changes in iron handling proteins 
in the kainate lesioned hippocampus and that occurring in AD, PD (Ong and 
Farooqui 2005; Chang et al. 2006). IRP1 expression was similar between AD 
and control brain, but IRP2 expression showed striking differences (Smith et al. 
1998). The IRP/IRE complex was also found to be more stable in AD brains 
(Pinero et al. 2000). Increased expression of IRP (particularly IRP2), together 
with a more stable IRP/IRE complex, could result in increased expression of iron 
transporters and decreased expression of ferritin, leading to a discrepancy 
between brain iron influx and iron binding capacity. This could result in iron being 
present in the unbound (ferrous) form capable of catalyzing free radical 
reactions. Since an IRE is present in the 5'-UTR of the Alzheimer's amyloid 
precursor protein (APP) transcript (Zubenko et al. 1992; Bodovitz et al. 1995; 
Rogers et al. 2002), the changes in IRP may also affect the expression of APP 
and amyloid β-peptide formation. The latter is itself a free radical (Hensley et al. 
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1994), or could interact with iron to generate free radicals (reviewed in Huang et 
al. 2004). 
Further studies are necessary to determine the role of IRPs in human and 
animal models of neurodegeneration. Possible factors that could affect IRP, and 


















III. Distribution of Ferritin in the Rat Hippocampus after 
Kainate-Induced Neuronal Injury 
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1. Introduction 
 Iron is an important cofactor in a wealth of biological processes, including 
oxidative phosphorylation, gene regulation, and free radical homeostasis 
(Morgan 1996). On the other hand, failure to maintain appropriate levels of iron in 
humans is a feature of hereditary hemochromatosis, and certain 
neurodegenerative diseases (He et al. 1996; Qian and Wang 1998; Zoller et al. 
1999; Fleming et al. 1999). An important form of antioxidant defense is the 
sequestration of iron in organic storage forms such as ferritin (Hallgren and 
Sourander 1958; Octave et al. 1983; Lin and Girotti 1997; Garner et al. 1998; 
Oberle et al. 1998; Wilkinson et al. 2006). In vertebrates, the cytosolic form of 
ferritin consists of 2 subunits, termed H and L, encoded by separate genes 
(Caskey et al. 1983; Worwood et al. 1985). Twenty-four ferritin subunits 
assemble to form the apoferritin shell. Each apoferritin molecule of 450 kDa can 
sequester up to approximately 4500 iron atoms (Harrison and Arosio 1996; Liu 
and Theil 2005). The ratio of H to L subunits in ferritin can vary between 0.5 and 
5.0 (Cairo et al. 1991; Connor et al. 1995b), depending on the tissue type and 
physiologic status of the cell. Ferritin also has enzymatic properties, converting 
Fe2+ to Fe3+ as iron is internalized and sequestered in the ferritin mineral core. 
Use of recombinant ferritins has demonstrated that this function is an inherent 
feature of the H subunit of ferritin, which has a ferroxidase activity (Lawson 
1989). The importance of ferritin in regulating brain iron levels is shown by the 
recent identification of a basal ganglia disease (neuroferritinpathy) patient with a 
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mutation in the ferritin light chain presenting with extrapyramidal features similar 
to those of Huntington’s disease or parkinsonism (Curtis et al. 2001).  
 The content of cytoplasmic ferritin is regulated by the translation of ferritin 
H- and L- mRNAs in response to an intracellular pool of "chelatable" or "labile" 
iron (Aziz and Munro 1986; Rogers and Munro 1987). Thus, when iron levels are 
low, ferritin synthesis is decreased; conversely, when iron levels are high, ferritin 
synthesis increases. The regulatory response of ferritin to iron is largely 
posttranscriptional (Zahringer et al. 1976), and is due to the recruitment of stored 
mRNA from monosomes to polysomes in the presence of iron (Rogers and 
Munro 1987). This process is mediated by interactions between RNA binding 
proteins (iron regulatory proteins (IRP) 1 and 2) and a region in the 5' 
untranslated region of ferritin H and L mRNA termed the iron response element. 
IRP-1 is more abundant than IRP-2 in the liver, kidney, intestine and brain 
(Thomson et al. 1999). IRP-1 binds to the iron response element and represses 
ferritin translation when iron levels are low, but unbinds from the iron response 
element, thus allowing ferritin translation, when iron levels are high (reviewed in 
Torti and Torti 2002). In rats, ferritin is expressed predominantly in microglia at 
postnatal day five, but predominantly in oligodendrocytes by postnatal day thirty 
(Cheepsunthorn et al. 1998). In addition, oligodendrocyte precursor cells have 
been shown to internalize ferritin via clathrin-dependent receptor-mediated 
endocytosis (Hulet et al. 2000). 
 In kainate-induced neurotoxicity, the stimulation of kainate / AMPA 
receptors results in the activation of phospholipase A2, and rapid release of 
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arachidonic acid from neural membrane glycerophospholipids. This produces 
alterations in membrane fluidity and permeability, resulting in calcium influx, 
stimulation of lipolysis and proteolysis, production of lipid peroxides, depletion of 
ATP, and loss of reduced glutathione from the affected neurons (reviewed in 
Farooqui et al. 2001). 
 An increase in iron has been reported in the rat hippocampus, after 
kainate induced neuronal degeneration (Ong et al. 1999). The increase in iron 
occurred over weeks, and was accompanied by an increase in number of ferric 
and ferrous iron positive cells (Wang et al. 2002b). An increased expression of 
DMT1 has been observed in astrocytes in the degenerating hippocampus, 
concomitant with the rise in iron, indicating that the increase in iron could arise as 
a result of increased iron transport across the blood brain barrier (Wang et al. 
2002a; 2003). Ferritin is capable of sequestering iron and keeps iron in the non-
reactive status. However, it is not known whether this increase in iron is 
accompanied by any increase in ferritin. The present study was therefore carried 
out, using immuncytochemistry and electron microscopy, to investigate the 
distribution and change of  ferritin, ferric iron and ferrous iron, and any correlation 
between ferritin and iron in the rat hippocampus after kainate lesion.  
 
2. Materials and methods 
2. 1. Animals and kainate injection 
 This was carried out as described in Chapter II, II. 2. 2 (Page 61).  
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2. 2. Histochemical staining for iron 
2. 2. 1. Perl's stain for ferric Iron 
 This was carried out by following a protocol described previously 
(McManus and Mowry 1960). Sections were washed with distilled water and 
immersed in a potassium ferrocyanide mixture Perl's solution, containing 1 part 
10% aqueous, potassium ferrocyanide (Sigma, St. Louis, USA, analytical grade) 
and half a part of 10% hydrochloric acid for 30 min, followed by 6 washes of 
distilled water at 5 min each. Control sections were incubated with potassium 
ferrocyanide solution alone. 
 
2. 2. 2. Turnbull's blue stain for ferrous iron 
 This was carried out as previously described (McManus and Mowry 1960). 
Sections were washed with distilled water and immersed in a potassium 
ferricyanide mixture, containing 1 part 2% potassium ferricyanide (Sigma, 
analytical grade) and 1 part 2% hydrochloric acid for 30 min, followed by washing 
with distilled water 6 times for 5 min each. Control sections were incubated in 
potassium ferricyanide solution alone. 
 
2. 2. 3. Diaminobenzidine enhancement of Perl's stain and Turnbull's blue stain 
 The Perl's or Turnbull's blue stained sections were immersed for 15 min in 
0.05% 3, 3-diaminobenzidine tetrahydrochloride (DAB) solution in 0.1 M 
phosphate buffer (pH 7.4). This was followed by addition of H2O2 to the solution 
(0.5ml 1% to 100ml DAB solution). The sections were immersed in the solution 
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for a further 15 min, following which they were rinsed in distilled water for 30 min 
(Nguyen-Legros et al. 1980; Hill and Switzer 1984). A number of sample sections 
were examined microscopically during the DAB reaction, to ensure that only blue 
cells stained for Perl's stain or Turnbull's blue stain were converted to brown cells 
with DAB, i.e., that there were no spurious DAB-labeled cells that had not been 
stained by Perl's or Turnbull's blue stain.  
 
2. 3. Immunohistochemistry 
 This was carried out as described in Chapter II, II. 2. 4(Page 64). The 
sections were then incubated overnight with primary antibody, a rabbit polyclonal 
antibody to ferritin (Dako, Glostrup, Denmark, diluted 1:100). The antibody was 
raised against the H and L forms of human ferritin, and has been shown to cross 
react against the H and L forms of rat ferritin (Leibold et al. 1984).  
2. 4. Electron microscopy 
 This was carried out as described in Chapter II, I. 2. 5 (Page 52).  
2. 5. Double immunofluorescence labeling 
 A further four 2 weeks post-kainate injected rats and four 8 weeks post-
kainate injected rats were used. The rats were deeply anesthetized by 
intraperitoneal injection of 1.5 ml 7% chloral hydrate, and transcardially perfused 
with normal saline, followed by a fixative, consisting of 4% paraformaldehyde in 
0.1M phosphate buffer (pH 7.4). The brains were dissected out, and blocks 
containing the dorsal hippocampus sectioned coronally at 40 µm using a freezing 
microtome. The sections were processed for free-floating double 
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immunofluorescence labeling or double labeling of ferritin and Perl's stain or 
Turnbull's blue stain. Sections intended for  double immunofluorescence labeling 
were washed for 3 h in phosphate-buffered saline containing 0.1% Triton (PBS-
Tx) to remove traces of fixative, and immersed for 1 h in a solution of 5% normal 
goat serum and 1% bovine serum albumin in PBS-Tx to block non-specific 
binding of antibodies. They were then incubated overnight with a rabbit 
polyclonal antibody to ferritin (Dako, Glostrup, Denmark, diluted 1:100) and 
mouse monoclonal antibody to glial fibrillary acidic protein (GFAP, Chemicon, 
Temecula, USA, diluted 1:1000) or CNPase (sigma, St. Louis, USA, diluted 
1:100) or OX42 (Serotec, Oxford, UK, diluted 1:100).The sections were then 
washed three times in PBS, and incubated for 1h at room temperature in 1:200 
dilution of FITC-conjugated goat anti-mouse IgG, and Cy3-conjugated goat anti-
rabbit IgG (both from Chemicon). The sections were mounted and examined 
using an Olympus FluoView FV500 confocal microscopy. Control sections were 
incubated with pre-immune rabbit and mouse serum instead of primary 
antibodies. These showed absence of staining. 
 
2. 6. Double labeling with immunohistochemistry for ferritin and Perl's stain or 
Turnbull's blue stain 
 This was carried out as described above, except that DAB enhancement 
of the Perl's stain or Turnbull's blue stain was omitted, allowing the visualization 
of DAB (ferritin and iron reaction products on the same section.   
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2. 7. Cell counts  
 The number of stained cells in the hippocampus was counted in a blinded 
fashion, using a light microscope. Three immunostained or histochemically 
stained sections from each of the four rats in each category were counted, and 
the results were expressed as mean number of stained cells / mm2. The results 
were subjected to statistical analysis using student’s T-test. p < 0.05 was 
considered significant.  
 
3. Results 
3. 1. Light microscopy 
3. 1. 1. Saline injected rats (Fig. 3. 1- 2). 
 No ferric iron (Fig. 3. 2A) or ferrous iron (Fig. 3. 2B) staining, and very light 
ferritin immunoreactivity was observed in the hippocampus of saline injected rats 
(Fig. 3. 2C). The ferritin labeled cells had small rounded cell bodies, and thin and 
straight processes characteristic of oligodendrocytes.  
 
3. 1. 2. Kainate lesioned rats 
Three days after kainate injection (Fig. 3. 1- 2) 
 Nissl stained sections showed death of neurons at this time (Fig. 3. 2D). 
An increase in ferritin staining was observed (Fig. 3. 2E).  
 
One to four weeks after kainate injection (Fig. 3.1- 3). 
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 An increase in ferritin staining was observed in one week post-kainate 
injection (Fig. 3. 2F). An increase in ferric iron (Fig. 3.  3A), and a small increase 
in ferrous iron (Fig. 3. 3B) positive cells were observed in the degenerating 
hippocampus. Large numbers of ferritin positive glial cells were observed in the 
degenerating CA fields at these times (Fig. 3. 3C). The ferritin labeled cells have 
rounded cell bodies and irregular all outlines, including filopodium and ruffles on 
the all membrane surface. The ferritin cells were found to be mostly microglia, by 
double immunofluorescence labeling (see below). 
 
Eight to twelve weeks after kainate injections (Fig. 3. 1, 3) 
 A further increase in ferric (Fig. 3. 3D) and ferrous iron (Fig. 3.  3E), a 
decrease in ferritin staining was observed at this time, compared to earlier time 
intervals (Fig. 3.  3F).  
 
3. 2. Electron microscopy (Fig. 3. 4) 
 The ferritin positive cells had small cell diameters (mean diameter = 9µm), 
and regular cell outlines. The nucleus contained dense heterochromatin clumps 
on the inner aspect of the nuclear envelope. The cytoplasm contained small 
numbers of cytoplamic organelles, including mitochondria and short cisternae of 
endoplasmic reticulum (Fig. 3. 4A, B). Ferritin labeling was associated with free 
ribosomes and ribosomes of the endoplasmic reticulum (Fig. 3. 4B). In addition to 
microglia, ferritin was also observed in endothelial cells of blood vessels in the 
 84
degenerating CA field (Fig. 3. 4C). Cells with dense bundles of glial filaments 
characteristic of astrocytes were not labeled (Fig. 3. 4A). 
 
3 .3. Double labeling 
3. 3. 1. Double labeling of ferritin with glial markers (Table  3. 1, Fig. 3. 5) 
 The kainate lesioned rats after 2 weeks post-injection showed that ferritin 
positive cells were mostly double labeled with OX42, confirming that they were 
microglia (Fig. 3. 5A). Ferritin positive cells were little double labeled with 
CNPase (Fig. 3. 5B), and not double labeled with GFAP (Fig. 3. 5C). The kainate 
lesioned rats after 8 weeks post-injection showed that ferritin positive cells were 
mostly double labeled with OX42 (Fig. 3. 5D).  
 
3. 3. 2. Double labeling of ferritin or glial marker with ferric or ferrous iron (Table  
3. 1, Fig. 3. 5) 
 In the 2-week post-kainate injected animals, 20.1+7.7 % and 9.2+6.2 % of 
ferritin positive cells were double labeled for ferric or ferrous iron respectively, 
whilst 55.6+8.8 % of ferric and 46.1+6.8 % of ferrous iron positive cells were 
labeled for ferritin. The number of ferric and ferrous iron positive cells increased 
at 2 months after kainate injection and at this time, 52.7+6.5 % and (23.1+2)% of 
ferritin positive cells were double labeled for ferric or ferrous iron respectively, 
whilst 52.3+4.9 % of ferric and 46.2+5.5 % of ferrous iron positive cells were 
labeled for ferritin. The number of ferrous iron positive cells at 2 months that were 
not double labeled for ferritin was also significantly greater than the number at 2 
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weeks (Table 3. 1). In particular, very heavily iron laden cells containing ferrous 
iron, and appearing almost spherical in outline, were not labeled for ferritin, 
indicating that in these cells, the lack of ferritin may be a factor in the iron being 
present in the ferrous state (Fig. 3. 5F). In addition to microglia, ferric or ferrous 
iron granules were also present in oligodendrocytes (Table 3. 1). 
 
4. Discussion 
 The present study aimed to elucidate the distribution of ferritin in the 
kainate-lesioned hippocampus. An increase in ferritin was observed in microglia 
in the kainate-lesioned hippocampus. The increase occurred from 3 days after 
kainate injection, and peaked at 4 weeks postinjection. Double immunolabeling 
showed that most of the ferritin positive cells in both the two week and two month 
post-kainate injected rats were double labeled for OX-42, a marker for microglia, 
whilst only a minority (approximately 10%) was double labeled for CNPase, a 
marker for oligodendrocytes. Non-specific binding by the ferritin antibody in the 
present study is unlikely, since a well-characterized antibody was used (Leibold 
et al. 1984). The antibody does not, however, distinguish between the H- and L- 
subunits of ferritin. 
 The observation that ferritin is present in both microglia and 
oligodendrocytes after kainate induced neuronal injury is consistent with the 
results of previous studies, which showed ferritin immunoreactivity in these two 
cell types. It has been reported that although the predominant cell type 
containing ferritin, transferrin, and iron throughout the brain at all ages is the 
 86
oligodendrocyte, ferritin and iron are also present in microglial cells in all brain 
regions, but are particularly abundant in the hippocampus (Benkovic and Connor 
1993). Ferritin immunoreacitvity in microglia, particularly, appeared to be 
upregulated following neurodegneration. A strong immunoreactivity for ferritin 
has been observed in the neuritic (senile) plaques in Alzheimer's disease 
hippocampus, and ferritin accumulation was mainly found on microglia (Grundke-
Iqbal et al. 1990; Roe et al. 1996). Another study reported that although many 
ferritin-positive oligodendrocytes are present in the Alzheimer's tissue, most of 
the ferritin-containing cells associated with senile plaques and blood vessels are 
microglia (Connor et al. 1992a). The increased expression of ferritin may be a 
general brain response to seizures and / or neuronal injury. An upregulation of 
the H-ferritin mRNA in the hippocampus was demonstrated in the genetic 
absence epilepsy rat from Strasbourg (GAERS) rat model of absence epilepsy 
(Lakaye 2002; Gorter et al. 2005). An increased ferritin expression was also 
described, after transient forebrain ischaemia (Kondo et al. 1995; Ishimaru et al. 
1996). 
 The expression of ferritin is increased by an increase in iron in the cell. An 
increase in iron level would result in IRP being unbound from ferritin mRNA, 
thereby increasing ferritin translation, and an increase in ferritin expression (Torti 
and Torti 2002). An increase in ferritin expression has, indeed, been reported 
after various conditions that increased iron levels in the brain. These include 
haemin treatment (Gonzales et al. 2002), iron-injection in the rat parietal cortex 
(Turner et al. 1998) and following subarachnoidal hemorrhage (Ozawa et al. 
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1994) or intracerebral hemorrhage (Wu et al. 2003). Increase in ferritin 
immunostaining has also been shown in the rat substantia nigra, after injection of 
a neurotoxin 6-hydroxydopamine (He et al. 1999), and it is likely that the increase 
in iron could cause the increased translation of ferritin in these tissues. 
 Increased iron in the hippocampus after kainate injection (Ong et al.1999; 
Wang et al. 2002a; and the present study) is therefore likely to cause increased 
ferritin expression in this tissue. Although ferritin cells are observed before iron 
positive cells could be demonstrated histochemically in this study, nuclear 
microscopy, which is a much more sensitive technique, showed that iron 
increase had occurred at least at the same time, or before the increase in ferritin 
(Ong et al. 1999). It is however, unlikely that iron is the only factor determining 
ferritin expression, since double labeling showed significant non-overlap between 
the ferritin and iron-positive cells. The number of ferrous iron positive cells at 2 
months that were not double labeled for ferritin was significantly greater than the 
number at 2 weeks. In particular, very heavily iron laden cells containing ferrous 
iron, and appearing almost spherical in outline were not labeled for ferritin (Fig. 3. 
5F), indicating that in these cells, the lack of ferritin may be a factor in the iron 
being present in the ferrous state. 
 What might be the cause of the non-overlap between ferritin and iron? In 
addition to iron levels, oxidative stress has also been shown to regulate ferritin 
expression(Tsuji 2005). Both transcriptional and post-transcriptional mechanisms 
have been implicated in ferritin induction by oxidants. Oxidants induce ferritin 
expression by directly targeting conserved regions of ferritin genes (Tsuji et al. 
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2000). Oxidative stress can also contribute to ferritin induction by inactivating 
IRP1 through reversible oxidation of critical cysteine residues (Cairo et al. 1996). 
In other experimental systems, however, oxidants have the opposite effect. 
Hydrogen peroxide was shown to activate IRP1, possibly through induction of a 
signaling pathway that mobilizes iron from the 4Fe-S cubane cluster 
(Pantopoulos and Hentze 1998). This results in reduced ferritin synthesis 
posttrancriptionally, potentially leaving the cell more susceptible to oxidative 
injury (Pantopoulos and Hentze 1995). One possibility, therefore is that increased 
oxidative stress as a result of increased iron accumulation in microglia, could 
result in the observed decreased expression of ferritin in these cells at long time 
intervals after kainate injection. This could result in some of the iron being 
present in the ferrous form. Since ferrous iron is capable of generation of free 
radicals, this might contribute to neuronal injury, at long time intervals after 
kainate injection. A second possibility, in view of our recent observation of 
increased expression of iron regulatory protein-1 (IRP-1) in microglial after 
kainate injury, is that increased binding of IRP to IRE in microglia could lead to 
decreased expression of ferritin in these cells. 
 The time course of the ferritin response, and the relationship between 
ferritin and iron containing cells, as described in this study on kainate induced 
excitotoxicity, may also occur following other types of neuronal injury (Irace et al. 
2005). In particular, the observation that brain regions undergoing 
neurodegeneration and containing high ferritin levels could also contain high 
amounts of non-ferritin associated and presumably unbound, ferrous iron, 
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particularly at long time intervals after neuronal injury, may help in the 
interpretation of data from MRI studies of human neurodegenrative diseases. An 
increased ferritin has been observed in the basal ganglia of patients with early-
onset Alzheimer's disease and Parkinson's disease patients (Bartzokis et al. 
1999; 2000; 2004). The present study shows that this does not necessarily imply 
that there are increased amounts of bound iron. In fact, it has been postulated 
that iron in ferritin may be mobilized by activated microglia, resulting in it being 
available in the reactive, unbound form (Yoshida et al. 1995b; 1998). In contract 
to early-onset Parkinson’s disease, a reduced level of ferritin, has been observed 
in MRI scans of the substantia nigra in patients with late-onset Parkinson’s 
disease (Bartzokis et al. 1999), and postmortem specimens from brains of 
Parkinson’s' disease patients (Dexter et al. 1990). Together with a report 
increase in iron levels in the substantia nigra compacta on these patients 
(Jellinger et al. 1990), these findings suggested that unbound iron may be a 
source of free radical damage in these diseases (Dexter et al. 1990). Inconsistent 
changes in iron and ferritin were detected in postmortem brain specimens from 
Alzheimer's disease patients, compared to age match controls (Connor et al. 
1992b). Some investigations revealed a reduced half-life of both ferritin chains 
due to oxidation. This was due to the removal of oxidized ferritin by the 
proteasomal system (Mehlhase et al. 2004). It has reported that a mutation in the 
ferritin light polypeptide gene is associated with neurodegenerative diseases 
(Vidal et al. 2004).  
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 The precise mechanism by which increased iron in the center of a glial 
scar could cause tissue injury in adjacent neural tissues remains unknown. The 
hydroxyl radicals that are formed by catalytically active iron in the center of the 
glial scar are highly reactive and unlikely to travel beyond the immediate vicinity 
of the glial cells to affect distant tissues. These radicals may, however, act on 
neural processes that are passing through the damaged tissues, resulting in 
retrograde changes in neurons at distant sites. There are indications that iron 
mediated neuronal death in Parkinson’s' disease may, indeed, proceed 
retrogradely (Gotz et al. 2004), and further work is necessary to investigate this 







IV. Distribution of Ferroportin-1 and Ceruloplasmin in 





Iron is an essential element for the function of the central nervous system. 
However, accumulation of excess iron can generate highly toxic free radicals 
through Fenton reaction (Ercal et al. 2001), and play a role in pathogenesis of 
some neurodegenerative diseases (Sayre et al. 1999; Thompson et al. 2001). 
Iron homeostasis in brain is maintained by several iron handling proteins 
such as transferrin, transferrin receptor, DMT1, ferritin and iron regulatory 
proteins. DMT1 is a recently discovered metal transporter, which has an 
unusually broad substrate range including Fe2+,Mn2+, Cu2+, Pb2+, etc. (Gunshin et 
al. 1997). It mediates active proton-coupled transmembrane transport including 
the transport of iron not only across the cell membrane but also out of the 
endosomes (Andrews 1999b). The DMT1 has been thought to play a role in brain 
iron influx (Burdo et al. 1999, Wang et al. 2002a). At least four major mammalian 
DMT1 isoforms resulting from alternative splicing at the 5'- (exon1A or exon1B) 
and 3'- (IRE or non-IRE form) ends of pre-messenger RNA are known (Hubert 
and Hentze 2002). The IRE form of DMT1 (+IRE DMT1) has an iron responsive 
element in the 3' untranslated region, whereas the non-IRE form of DMT1 (-IRE 
DMT1) lacks the IRE and its C-terminal 18 amino acids are replaced by a novel 
25 amino acid segment (Lee et al. 1998).  
Ferroportin-1 (FP, also known as Ireg1, MTP) is the only putative iron 
exporter identified to date. Mouse FP cDNA encodes a protein 570 amino acids 
in length with a predicted mass of 62 kDa (Abboud and Haile 2000; Donovan et 
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al. 2000; McKie et al. 2000; Ganz 2005). Sequence analysis of FP mRNA 
revealed the presence of an iron response element (IRE) in its 5’ untranslated 
end .FP is located at the basolateral membrane of duodenal enterocytes, where 
it mediates iron export into the bloodstream (Vulpe et al. 1999). Iron export from 
nonintestinal cells requires Ceruloplasmin (Cp) (Harris et al. 1999). Cp is an 
abundant serum alpha-2 glycoprotein and belongs to a family of multi-nuclear 
‘blue’ copper oxidases (Hellman and Gitlin 2002). Cp has ferroxidase activity, can 
convert Fe2+, likely exported by FP, to Fe3+ that is loaded onto Tf for transport in 
the plasma (Hellman and Gitlin 2002). In the brain, recent studies has 
demonstrated that Cp is synthesized as a glycophosphatidylinositol (GPI)-
anchored protein generated by alternative splicing of exons 19 and 20 in 
astrocytes and Sertoli cells (Patel and David, 1997; Patel et al. 2000; Salzer et al. 
1998).  The GPI form of ceruloplasmin is expressed in astrocytes in vitro. It works 
in concert with the iron transport protein ferroportin-1, to cause iron efflux from 
these cells (Jeong and David 2003; Aguirre et al. 2005).   
Our previous studies have shown an increase in iron accumulation in the 
rat hippocampus after kainate lesions (Ong et al. 1999; Wang et al. 2002b). The 
increase in iron was accompanied by an increase in two isoforms of DMT1 
immunolabeling in astrocytes, suggesting that the increased DMT1 expression 
could be responsible for the iron accumulation. However the iron-laden cells 
were not astrocytes but mainly microglia or oligodendrocytes in kainate injected 
rat hippocampus. This indicates that there may be iron efflux mechanism 
involved in astrocytes in kainate-induced brain injury. Till date, the role of iron 
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exporters such as FP and Cp in neurodegeneration is little known. The present 
study was therefore carried out to study the distribution and time course of FP 
and Cp, in the hippocampus after kainate lesions, and any correlation between 
iron importer and iron exporter.  
2. Materials and methods 
2. 1. Antibodies 
Affinity-purified rabbit polyclonal antibodies to +IRE DMT1, -IRE DMT1 and FP 
were purchased from Alpha Diagnostic International (San Antonio, USA). 
Antibodies to the two forms of DMT1 were prepared by from the following C-
terminal peptides: +IRE peptide (545–561) and -IRE peptide (547–568). The 
antibody to FP was raised against 19-aa peptide sequence within cytoplasmic C-
terminus of mouse FP. The whole antiserum to human ceruloplasmin were 
purchased from Sigma (St Louis, USA), which was developed in goat using Cp 
isolated from fresh normal adult human serum as the immunogen.  
2. 2. Animals and kainate injection 
This was carried out as described in Chapter II, II. 2. 2 (Page 61). 
2. 3. Western blot analysis 
 This was carried out as described in Chapter II, II. 2. 3 (Page 62). The 
PVDF membrane was then incubated overnight in primary antibodies, the 
polyclonal antibodies to FP (1:500), Cp (1:10,000), + IRE DMT1 (diluted 1:250) 
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and -IRE DMT1 (1:250). Immunoreactivity was visualized using a 
chemiluminescent substrate (Supersignal West Pico, Pierce, Rockford, USA).  β-
actin was also carried out for loading control.  
2. 4. Immunohistochemistry 
 This was carried out as described in Chapter II, II. 2. 4(Page 64).  The 
sections were then incubated overnight with primary antibodies to FP (1:200), Cp 
(1:1,500), +IRE DMT1 (1:100) or -IRE DMT1 (1:00). Control sections were 
incubated with PBS,  pre-immune rabbit serum, and antigen absorbed antibody 
instead of primary antibody. The antigen-absorbed antibodies were prepared by 
incubating the 50µg/ml solution of +IRE DMT1, -IRE DMT1, FP immunizing 
peptide with the FP, +IRE DMT1 and -IRE DMT1 antibodies overnight 
respectively. These showed absence of immunostaining. 
2. 5. Electron microscopy 
This was carried out as described in Chapter II. I. 2. 5 (Page 52).  
2. 6. Double immunofluorescence labeling 
 This was carried out as described in Chapter II, II. 2. 6(Page 65). The 
sections were then incubated overnight with polyclonal antibodies to FP (1:200) 
or Cp (1:1,500) and mouse monoclonal antibody to glial fibrillary acidic protein 
(GFAP, Chemicon, Temecula, USA, diluted 1:1000). The sections were then 
washed three times in PBS, and incubated for 1hr at room temperature in 1:200 
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dilution of FITC-conjugated goat anti-mouse IgG and Cy3-conjugated goat anti-
rabbit IgG (both from Chemicon), or FITC-conjugated bovine anti-mouse IgG and 
Texas Red -conjugated bovine anti-goat IgG (both from Santa Cruz, Santa Cruz, 
USA). The sections were mounted and examined using an Olympus FluoView 
FV500 confocal microscopy.  
2. 7. Cell counts  
 This was carried out as described in Chapter II, II. 2. 7(Page 66). 
3. Results 
3. 1. Western blot analysis (Fig. 4. 1) 
Antibody to FP and Cp both detected single bands at ~ 62 kDa and ~135 
kDa in hippocampi of saline- and kainate-injected rats, consistent with the 
expected molecular weight of respective proteins. Antibody to +IRE DMT1 and  -
IRE DMT1 both detected several bands at ~40Ka, 45 kDa, ~50 kDa and  ~65 
kDa in hippocampi of saline- and kainate- injected  rats,  consistent with the other 
reports. DMT1 have different isoforms and may exist in multiple forms having a 
variety of molecular weights (Lis et al. 2004). Increased density of detected 
bands were observed in kainate injected rats, compared to saline-injected rats. 
3. 2. Light microscopy 
3. 2. 1. Saline injected rats (Table 4. 1, Fig. 4. 2) 
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 No or little FP (Fig. 4. 2A) or Cp (Fig. 4. 2B), +IRE DMT1 (Fig. 4. 2C), -IRE 
DMT1 (Fig. 4. 2D) immunoreactivity was observed in the hippocampus of saline 
injected rats. Medial Cp immunoreactivity was observed in pyramidal neurons 
(Fig. 4. 2B).  
3. 3. 2. Kainate lesioned rats 
Three days after kainate injection (Table 4. 1, Fig. 4. 2) 
Loss of neurons was observed in field CA1 of the hippocampus, in Nissl stained 
sections (data not shown). A little increase in FP (Fig. 4. 2E), +IRE DMT1 (Fig. 4. 
2G), -IRE DMT1 (Fig. 4. 2H) immunoreactivity was observed in glial cells in the 
affected CA fields at this time. The affected areas showed medial Cp 
immunoreactivity in degenerating pyramidal neurons and glial cells (Fig. 4. 2F). 
One to four weeks after kainate injection (Table 4. 1, Fig. 4. 3)  
Loss of neurons, and large numbers of glial cells were observed in fields CA1 
and CA3 of the hippocampus, in Nissl stained sections at these times (data not 
shown). A further increase in FP (Fig. 4. 3A), Cp (Fig. 4. 3B), +IRE DMT1 (Fig. 4. 
3C) and –IRE DMT1 (Fig. 4. 3D) immunoreactivity was observed in the 
degenerating CA fields at these times. The FP, Cp, + DMT1 or –IRE DMT1 
immunoreactivity was observed in a population of glial cells with large diameter 
processes that tapered gradually from the cell bodies, characteristic of 
astrocytes. Their identity was confirmed at electron microscopy and by double 
immunofluorescence labeling with GFAP, a marker for astrocytes (see below). 
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No or little  Cp immunoreactivity was observed in pyramidal neurons at these 
times (Fig. 4. 1, 3B) The numbers of FP, Cp, + DMT1 or –IRE DMT1 positive glial 
cells peaked at 2 weeks post-kainate injected rats (470+68, 437+99,734+141 or 
718+135 cells / mm2), and were significantly greater than those of saline injected 
controls (16+19 17+15 , 58+31, 66+27 cells / mm2)(Table 4. 1, p < 0.05). The 
increased number of  the FP and Cp positive glial cells  was significantly smaller 
than that of the +IRE DMT1  and –IRE DMT1 positive cells  at 2 weeks or 4 
weeks postinjection (both p < 0.05, Table 4. 1).  
Eight weeks after kainate injections (Table 4. 1, Fig. 4. 3) 
 A dense glial scar was observed in the lesioned CA fields, in Nissl 
sections at this time (data not shown). A decrease in FP (Fig. 4. 3E), Cp (Fig. 4. 
3F), +IRE DMT1 (Fig. 4. 3G) or –IRE DMT1 (Fig. 4. 3H) immunoreactivity was 
observed the degenerating CA fields at this time, compared to two weeks 
postinjection.  
3. 3. Electron microscopy (Fig. 4. 4) 
Large numbers of FP and Cp positive cells were found in the degenerating 
CA fields of rats that had been injected with kainate 2 weeks previously. The FP 
(Fig. 4. 4A, B), Cp (Fig. 4. 4C, D) positive cells all had large cell bodies with 
irregular cell outlines. The nucleus contained evenly dispersed fine 
heterochromatin clumps, and absence of marginated heterochromatin on the 
inner aspect of the nuclear envelope. The cytoplasm contained dense bundles of 
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glial filaments. They thus had features of astrocytes.  Some of the labeled 
processes were observed to form end feet around blood vessels (Fig. 4. 4B, D), 
while no obvious labeling was observed in endothelial cells. 
3. 4. Double immunofluorescence labeling (Fig. 4. 5, Table 4. 2) 
 Dense staining for FP and Cp was observed in glial cells, in the two weeks 
post-kainate injected rats. The FP (Fig. 4. 5A, B, C), Cp (Fig. 4. 5D, E, F) positive 
cells had large diameter processes that tapered gradually from the cell bodies, 
and were mostly double labeled for GFAP, indicating these cells are astrocytes.  
4. Discussion 
The present study aimed to elucidate the distribution and time course of 
the two iron exporter proteins (FP and Cp) and DMT1 isoforms in the kainate-
lesioned hippocampus. An increase in FP, Cp, + DMT1 or –IRE DMT1 was 
observed in glial cells in the kainate-lesioned hippocampus. The increase 
occurred from 3 days after kainate injection, peaked at 2 weeks postinjection, 
and decreased after 4 weeks. Double immunofluorescence labeling and electron 
microscopy showed that the FP and Cp were expressed in astrocytes. Western 
blot analysis showed that the detected band of FP, Cp, + DMT1 and –IRE DMT1 
were consistent with the expected molecular weight of respective proteins. 
Increased density of Western blot in kainate-injected rats compared to the 
controls was consistent with the immunohistochemistry results.  The number of 
+IRE DMT1 cells after kainate lesions was approximately equal to the number of 
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–IRE DMT1 cells. This data was consistent with our previous study that showed 
increased expression of DMT1 (both +IRE and –IRE forms) and –IRE DMT1 in 
astrocytes in the hippocampus after kainate injury. This indicated that both 
increased isoforms of DMT1 could contribute to iron accumulation after kainite 
injury. The number of +IRE DMT1 and –IRE DMT1 positive cells was significantly 
greater than that of the FP and Cp positive cells at 2-week and 4-week after 
kainate injection. The mismatch of iron influx (DMT1) and iron efflux (FP and Cp) 
suggests that this might be a cause of iron accumulation in the brain after kainate 
injury.  
Though increased DMT1 was expressed in astrocytes which might play an 
important role in iron uptake, the iron-laden cells were not astrocytes but mainly 
microglia or oligodendrocytes in kainate injected rat hippocampus. This indicates 
that there may be iron efflux mechanism involved in astrocytes in kainate-
induced brain injury. Recent work showed that GPI-Cp colocalized on the 
astrocyte cell surface with FP and was physically associated with FP. In addition, 
FP alone was unable to efflux iron from astrocytes in the absence of GPI-Cp or 
secreted Cp. The coordinated actions of GPI-Cp and FP might be required for 
iron efflux from neural cells (Jeong and David 2003).  In cell level, Increased FP 
and Cp expression may export ferrous iron from cells, which can reduce iron-
induced free radical as scavenger of oxidative stress and a defense mechanism 
(Osaki et al. 1966; Aouffen et al. 2001). In vivo, this study showed that the 
pattern of increased Cp expression in astrocytes was parallel with that of FP.  
Electronic microscopy showed that FP and Cp were expressed in cytoplasm, 
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process, astrocytic end feet around blood vessels, whereas little expression was 
observed in endothelial cells of blood vessel wall. This indicates that increased 
FP and Cp may not export iron into bloodstream but brain parenchyma, and then 
the exported iron is absorbed by other neural cells such as oligodendrocytes and 
microglia, which lead to iron accumulation in these cells.  The activation of the 
CP/FP system in brain injury may be part of the iron translocation, from 
astrocytes to other cells, and further damage the brain, rather than being a 
defense mechanism.  
However, this is not consistent with the existence of the human genetic 
disorder aceruloplasminemia that is characterized by the absence of Cp and 
marked accumulation of iron in the CNS (Harris et al. 1995; Gitlin 1998; Miyajima 
2003; Haemers et al. 2004). It has been reported that disruption in the 
expression of FP or Cp proteins is a likely cause of the altered brain iron 
metabolism observed in age-related neurodegenerative diseases, including 
Parkinson’s disease, Alzheimer’s disease (Qian and Wang 1998; Hahn et al. 
2004).  
The mechanisms through which CP and FP are induced in pathological 
brain conditions, such as inflammatory and/or neurodegenerative diseases, has 
still to be uncovered. Fp expression is responsive to iron and inflammatory stimuli 
(Zoller et al. 2001; Yamaji et al. 2001; Yang et al. 2002; Martini et al. 2002; di 
Patti et al. 2004; Chen et al. 2005). The mRNA possesses an iron responsive 
element in the 5’ untranslated region (UTR) that binds IRPs and may confer iron 
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dependent regulation of luciferase in desferrioxamine-treated COS7 cells. In 
agreement with this model, the ferroportin promoter is responsive to iron in 
HepG2 and CaCO2 cells: deletion of various promoter fragments does not 
abrogate iron-dependent regulation, while removal of the IRE element leads to 
loss of iron control (Lymboussaki et al. 2003). In vivo, additional mechanisms 
may be important in controlling ferroportin expression, particularly in the 
duodenum, in response to stimuli such as hypoxia or erythropoietic demands 
(Abboud and Haile 2000; McKie et al. 2000; Frazer et al. 2003). CP has been 
recognized to be an acute phase protein many years ago, and it is known to be 
induced in response to proinflammatory stimuli, such as IL-1b (Barber and 
Cousins 1988; ,chang et al. 2001; Kuhlow et al. 2003; di Patti et al. 2004), IFN-
gamma (Mazumder et al. 1997), and also in iron deficiency and hypoxia 
(Mukhopadhyay et al. 2000). Further studies are required to elucidate the 





V. Heme Oxygenase-1 Activity After Excitotoxic Injury – 
Immunohistochemical Localization of Bilirubin in 
Neurons and Glial Cells and Deleterious Effects of Heme 




The heme oxygenase (HO) family of enzymes (E.C. 1:14:99:3) mediates 
heme catabolism in a wide range of species. They comprise two constitutively 
expressed isoforms, HO-2 and HO-3, and an inducible isoform, HO-1 (Maines et 
al. 1986; McCoubrey et al. 1997). HO-1 and HO-2 are encoded by different 
genes and except for the heme-binding domain, exhibit significant differences 
with regard to molecular weight, electrophoretic mobility, susceptibility to 
proteolysis, tissue distribution and regulation (Shibahara et al. 1985; Cruse and 
Maines 1988; Maines 1992). HOs are located within the endoplasmic reticulum, 
where they cleave the heme molecule to produce biliverdin and carbon 
monoxide, and free ferrous iron. The biliverdin is subsequently reduced to 
bilirubin by biliverdin reductase (Maines 1988). HO-1 expression is responsive to 
various stimuli that cause oxidative stress (Keyse and Tyrrell 1989; Applegate et 
al. 1991; Maines 1992; Abraham et al. 1995). Induction of this enzyme may 
protect cells by augmenting the breakdown of pro-oxidant heme to the radical 
scavenging bile pigments biliverdin and bilirubin (Stocker et al. 1987a,b; Dore et 
al. 1999a,b; Baranano and Snyder 2001). In contrast, HO-2 is not induced by 
oxidative stress (Maines et al. 1992).  
 Increased immunoreactivity to HO-1 is present in neurons and astrocytes 
of the hippocampus and temporal cortex in Alzheimer’s disease, and in 
substantia nigra neurons in Parkinson’s disease (Schipper et al. 1995; 1998; 
Schipper 2004). Increased HO-1 immunoreactivity is also present in astrocytes in 
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the cerebral cortex at sites of traumatic brain injury (Fukuda et al. 1996), and in 
microglia, astrocytes and neurons, in the infracted and perifocal areas after 
transient middle cerebral artery occlusion (Koistinaho et al. 1996). Studies using 
a potent analog of glutamate, kainate to induce excitotoxic injury to the 
hippocampus have shown that HO-1 protein level was strongly enhanced after 
kainate treatment, although HO-2 level was not changed. One day after 
treatment, the protein level of HO-1 reached a maximum and then gradually 
decreased over a period of three to seven days (Matsuoka et al. 1998; Lu and 
Ong 2001). At postinjection weeks 1-3, HO-1 was observed in glial cells in the 
center of the lesion, and also in neurons at the perifocal region of the glial scar 
(Lu and Ong 2001). 
 Till date, it is unclear whether the increased HO-1 expression in the above 
conditions is accompanied by increased enzymatic activity. The activated HO-1 
would release free ferrous iron into cytoplasm, and whether this contributes to 
iron accumulation in kainate-induced neuronal injury is not known.  The present 
study was therefore carried out to compare the immunoreactivity of HO-1 with the 
product of HO-1 catalyzed reactions, bilirubin and iron, to determine if the 
increased HO-1 expression was accompanied by increased enzymatic activity, 
and any correlation with iron accumulation in the kainate lesioned hippocampus. 
The effect of any HO activity on neuronal survival in this model was also 
determined, using intraperitoneal injections of a blood-brain-barrier permeable 
inhibitor of HO. 
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 2. Materials and methods 
2. 1. HO-1, bilirubin, and iron after kainate injection 
2. 1. 1. Animals and kainate injection 
This was carried out as described in Chapter II, II. 2. 2 (Page 61). 
2. 1. 2. Immunohistochemistry 
This was carried out as described in Chapter II, II. 2. 4(Page 64). The sections 
were then incubated overnight with primary antibodies, mouse monoclonal 
antibodies to HO-1 (OSA-111, Stressgen, diluted 1:100 in PBS) or bilirubin 
(24G7, Shino-Test Co, Tokyo, diluted 1:250 in PBS). The affinity-purified 
antibody to HO-1 was raised against purified native rat HO-1 and detects a 32-
kDa protein (Lu and Ong 2001), corresponding to the apparent molecular mass 
of HO-1 on SDS-PAGE immunoblots in rat and mouse microsomal preparations. 
The antibody to bilirubin recognizes the conjugated and non-conjugated forms of 
bilirubin IXa but not other isobilirubins (Izumi et al. 1988).  
2. 1. 3. Histochemical staining for iron 
 Two sets of sections were stained using Perl's stain or Turnbull's blue 
stain with DAB enhancement, to demonstrate the presence of ferric or ferrous 
 107
iron respectively, in the degenerating hippocampus as previously described 
(McManus and Mowry 1960; Wang et al. 2002b).  
2. 1. 4. Cell counts and intensity measurements 
 The number of Nissl stained cells and HO-1 / bilirubin / ferric iron / ferrous 
iron stained cells in representative regions of field CA1 of the hippocampus of 
each rat was counted in a "blind" manner on coded slides from 3 sections with 
the help of a grid. The results were expressed as number of cells/ mm2. The 
mean number of stained cells/ mm2 was then calculated for each group of rats at 
a specific time interval after kainate injection (n = 4 per group), and the results 
compared, using 1-way ANOVA with Bonferroni's multiple comparison post-hoc 
test (SPSS for Windows software). p < 0.05 was considered significant. 
 The intensity of bilirubin immunostaining was measured with the aid of 
image analyzing software (Image-Pro Plus, version 4.1.0.0 for Windows 
95/NT/98; Media Cybernatics, Silver Spring, MD). Images were captured using a 
Zeiss Axiophot microscope fitted with a video camera. The mean intensity of 
bilirubin staining in neurons or astrocytes from the dorsal hippocampus of each 
rat was calculated, by densitometric measurements from at least 12 cells per 
section, in three sections. The results were expressed as grey values (1 indicates 
a white pixel and 255 indicates a black pixel). The mean intensity of staining of 
neurons or astrocytes was then calculated for each time interval after kainate 
injection, and the results compared, using 1 way ANOVA with Bonferroni's 
multiple comparison post-hoc test. p < 0.05 was considered significant. 
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2. 1. 5. Electron microscopy 
This was carried out as described in Chapter II. I. 2. 5(Page 52).  
2. 2.  Effect of HO inhibition on mortality and neuronal survival in kainate treated 
rats 
A futher twenty-six male Wistar rats (each weighing approximately 250 g) 
were injected with kainate as described above. The injected rats were randomly 
divided into two groups (13 rats each). The first group received an 
intracerebroventricular injection of kainate as described previously, followed 3h 
later by an intraperitoneal injection of a blood-brain-barrier permeable inhibitor of 
HO, tin protoporphyrin (SnPP) (50 μmol/kg), and twice daily intraperitoneal 
injection of 25 μmol/kg SnPP on the second and third post-kainate injection days. 
SnPP was obtained from Protoporphyrin Products (Ogden, USA). The SnPP was 
dissolved in 0.9% NaCl containing 0.1 M NaOH, brought to the desired volume 
with additional saline, and the pH adjusted to 7.4 using HCl. The solutions were 
freshly prepared every day, and protected from light. The second group of rats 
were used as controls. These received intracerebroventricular injection of kainate 
followed by intraperitoneal injections of normal saline, following the same 
schedule as the SnPP treated rats. There was some mortality of the rats, 
especially in the SnPP treated group (see below). The surviving rats were 
sacrificed at three post-kainate injected days by transcardial perfusion and blocks 
containing the hippocampus sectioned as described above. The sections were 
stained using the Nissl technique, and immunostained for microtubule associated 
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protein 2 (MAP2, Sigma, St Louis, USA, diluted 1:500) to demonstrate viable 
neurons. 
2. 3. Quantitation of surviving neurons 
Digital images of 6 hippocampal sections each, from either the Nissl or 
MAP2 stained sections from each rat were acquired at low magnification, and a 
curved line traced along the row of hippocampal pyramidal neuronal cell bodies 
from hippocampal fields CA1 to CA3. This was followed by a second trace, along 
the viable pyramidal neurons in the Nissl stained sections; or pyramidal neurons 
that showed immunolabeling in their cell bodies and dendrites, in the MAP2 
labeled sections. The ratio of the second to the first trace was calculated, to 
indicate the percentage of uninjured neurons in the CA fields. The mean and 
standard error were calculated for the SnPP or saline treated groups, and the 
results subjected to statistical analysis (Student's t-test). p < 0.01 was considered 
significant. 
3. Results 
3. 1. HO-1, bilirubin, and iron after kainate injection 
3. 1. 1. Saline injected rats (Table 5. 1, Fig. 5. 1, Fig. 5. 2A, B) 
Very little or no HO-1 or bilirubin staining was observed in the 
hippocampus of saline-injected control rats. No increase in ferric or ferrous 
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staining was observed in the saline injected rats, compared with normal 
untreated rats (Table 5. 1, Fig. 5. 1, 2A,B) (Wang et al. 2002). 
 
3. 1. 2. Kainate lesioned rats  
One day postinjection 
Nissl stained sections showed no loss of neurons in the lesioned 
hippocampus at this time. Increased HO-1 staining was observed in pyramidal 
neurons in the CA fields (Fig. 5. 2C), and in isolated astrocytes in the molecular 
layer of the dentate gyrus, and isolated dentate granule neurons (Fig. 5. 2D). 
An increase in bilirubin immunoreactivity was also observed in pyramidal 
neurons in the CA fields (Fig. 5. 2E), but no increase in staining was observed in 
astrocytes or granule neurons in the dentate gyrus (Fig. 5. 2F). No increase in 
ferric or ferrous staining could be detected in the hippocampus at this time (Table 
5. 1, Fig. 5. 1). 
Three days postinjection 
 Nissl stained sections showed loss of neurons in the lesioned CA fields 
(Fig. 5. 3A), but no obvious cell loss in the dentate gyrus. The affected areas 
showed a large increase in HO-1 immunoreactivity in pyramidal neurons (Fig. 5. 
3B). No immunoreactive astrocytes or granule neurons were observed in the 
dentate gyrus at this time. The increased HO-1 staining in the degenerating 
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pyramidal neurons is paralleled by an increase in bilirubin immunoreactivity in 
cell bodies and apical dendrites of these neurons (Fig. 5. 3C, 3D). The staining 
intensity of the bilirubin-positive pyramidal neurons was greater than that of 
astrocytes, in the degenerating CA fields at later time points (Fig. 5. 4, see 
below). As in the one-day post-kainate injected rats, no increase in bilirubin 
staining was observed in astrocytes or granule neurons in the dentate gyrus. 
Very little ferric and no ferrous staining were observed in glial cells in the 
degenerating CA fields (Table 5. 1, Fig. 5. 1). 
One, two and four weeks postinjection 
Nissl stained sections showed loss of neurons and large numbers of glial 
cells in the degenerating CA fields. As at earlier time intervals, no obvious cell 
loss was observed in the dentate gyrus. HO-1 immunoreactivity was observed in 
a population of glial cells with thick tapering processes, characteristic of 
astrocytes (Fig. 5. 5A). Bilirubin immunoreactivity was also observed in cells with 
features of astrocytes (Fig. 5. 5B-D). The number of bilirubin reactive astrocytes 
appeared more than that of HO-1 positive astrocytes, probably because of 
differences in sensitivity of the antibodies. An increase in number of ferric-labeled 
glial cells was observed in the degenerating CA fields at this time. In contrast to 
ferric-positivity, only a small number of glial cells were stained ferrous-positive at 
this time (Table 5. 1, Fig. 5. 1). 
Eight and twelve weeks postinjection 
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 The lesioned hippocampal fields appeared shrunken at these times. The 
astrocytes were lightly stained for HO-1 in the eight-week post-kainate injected 
rats (Fig. 5. 5E). The number of labeled glial cells was also reduced compared to 
earlier time intervals (Table 5. 1, Fig. 5. 1). 
 A similar decrease in bilirubin staining was observed in the lesioned CA 
fields at these times, compared to that at earlier time intervals (Fig. 5. 1, 5F). The 
number of labeled bilirubin positive cells was also reduced, compared to the one-
week or one month postinjected rats. Compared to the one-month postinjection 
rats, larger numbers of ferric and ferrous positive cells were observed in the 
degenerating CA fields (Fig. 5.1). 
3. 2. Electron microscopy 
 The bilirubin immunolabeled neurons were examined by electron 
microscopy. No staining was detected in neurons and glial cells in the 
hippocampus of normal saline-injected rats. In contrast, increased labeling was 
found in injured or degenerating neurons in the CA fields of rats that had been 
injected with kainate 3 days previously. The cell membranes and nuclear outlines 
were discontinuous, and large numbers of bloated mitochondria and vacuoles 
were observed in the cytoplasm. Intense bilirubin staining was observed in the 
cytoplasm of these neurons (Fig. 5. 6A).  
 Large numbers of bilirubin-labeled cells were also found in the 
degenerating CA fields of rats that had been injected with kainate 2 weeks 
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previously. These had large cell bodies with irregular cell outlines. The nucleus 
contained evenly dispersed fine heterochromatin clumps, and absence of 
marginated heterochromatin on the inner aspect of the nuclear envelope. The 
cytoplasm contained dense bundles of glial filaments. They thus had features of 
astrocytes (Fig. 5. 6B). Lighter bilirubin staining was observed in their cytoplasm 
than in that of neurons. 
3. 3. Effect of HO inhibition on mortality and neuronal survival in kainate treated 
rats 
Systemic administration of SnPP (50 μmol/kg/day I.P.) had a deleterious 
effect on mortality as well as cell survival after kainate injection. The survival rate 
was reduced to 69.3% (9/13) in the SnPP treated group, compared to 92.3% 
(12/13) in the control group. The surviving rats in the SnPP treated group also 
showed reduced number of surviving cells in the hippocampus. Nissl stained 
sections showed 38.5+ 22.9% cell survival in the SnPP treated group. This was 
significantly less than the 74.3 + 23% cell survival in the control group (p < 0.01, 
Fig. 5. 7). MAP2 immunostained sections showed 44.7 + 19.4 % cell survival 
after SnPP treatment. This was also significantly less than 77.6 + 20.8% cell 
survival in control (p < 0.01, Fig. 5. 7). 
4. Discussion 
 The present study was carried out to determine whether HO-1 induction in 
vivo after kainate induced excitotoxic injury is accompanied by increased 
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enzymatic activity, and whether this activity was protective, or perhaps 
destructive to neurons. As shown in our previous study, injection of kainate 
resulted in an early increase of HO-1 in hippocampal pyramidal neurons, 
followed by induction of the enzyme in astrocytes, at longer time intervals, i.e. 
weeks, after kainate injection (Lu and Ong 2001). In order to determine if the 
increased HO-1 was accompanied by an increase in enzymatic activity, bilirubin 
immunoreactivity was carried out in parallel with sections that had been stained 
for HO-1. It was found that bilirubin increase occurred in parallel with the 
increase in HO, indicating that HO-1 was enzymatically active. Very little or no 
bilirubin staining was observed in the hippocampus of saline-injected control rats. 
Intracerebroventricular injection of kainate resulted in loss of pyramidal neurons 
followed by a glial reaction in the degenerating CA fields. Dense 
immunoreactivity to bilirubin was observed in pyramidal neurons, whilst light 
staining was observed in astrocytes in the degenerating CA fields of the 
hippocampus. Electron microscopy showed that the neurons had features of 
injured or degenerating neurons, whilst the astrocytes had features of viable 
cells. The identity of heme proteins that are the substrates of HO-1 are unknown, 
but could include catalase, cytochrome b5, cytochromes P450, and nitric oxide 
synthase. Non-specific staining of the bilirubin antibody is unlikely, since a well 
characterized antibody was used. 
 At moderate concentrations, bilirubin is an antioxidant and can act as a 
neuroprotectant (Dore et al. 1999b). This may be due to the ability of bilirubin to 
scavenge peroxyl radicals (Stocker et al. 1987a; b). At high concentrations, 
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bilirubin can be a pro-oxidant. This effect has been attributed to its ability to 
inhibit or uncouple the respiratory electron transport chain (Day 1954; Ernster 
and Zetterstrom 1956; reviewed in Hansen 2000). The very high bilirubin 
concentrations in infants with kernicterus results in choreoathetosis, deafness, 
and occasionally mental retardation in the surviving infants (Perlstein 1960). 
These concentrations are in the high micromolar range - a thousand times the 
concentrations that are protective in vitro (Gourley 1997). Intracerebral injection 
of N-methyl-D-aspartate (NMDA), an excitotoxic analogue of glutamate resulted 
in greater injury in jaundiced 7-day-old Gunn rat pups than in nonjaundiced 
heterozygous littermate controls, indicating that very high neuronal 
concentrations of bilirubin could worsen excitotoxic injury (McDonald et al. 1998). 
In order to determine whether HO-1 induction / bilirubin formation after 
kainate could have a protective or destructive effect, kainate-injected rats were 
injected intraperitoneally with a blood-brain-barrier permeable inhibitor of HO, 
SnPP, and the effects of such treatment compared to rats that received kainate 
and saline injections. It was found that SnPP treatment did not improve neuronal 
survival. Instead, increased mortality was observed in rats treated with SnPP. 
Four SnPP injected rats versus one saline-injected rat died after kainate 
treatment. The surviving SnPP treated rats showed significantly less of the 
hippocampal fields that contained Nissl or MAP2 staining (an indicator of 
surviving neurons) compared to the saline-injected rats. These results indicate 
that HO-1 induction had a net protective effect on neurons in the kainate model 
of excitotoxic injury. 
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 The finding that HO inhibition by SnPP aggravates neuronal injury is 
consistent with recent findings of HO-1 knockout mice. HO-1 -/- mice showed 
significant accentuation of lesion volume (p < 0.001) after injection of NMDA into 
the striatum, as compared to wildtype mice (Ahmad et al. 2004). A lipophilic 
polyphenol that induces HO-1 expression, ethyl ferulate, has also been shown to 
protect rat neurons against oxidative stress (Scapagnini et al. 2004). Stroke 
damage has also been reported to be substantially worsened in HO-2 knockout 
mice (Dore et al. 1999a). It is therefore likely that the levels of bilirubin formed 
after kainate induced excitotoxicity is within the range of antioxidant effect of 
bilirubin. The intensity of HO-1 immunolabeling in neurons was found to be only 
1.6 fold, compared to the immunolabeled astrocytes in this study. In addition, it is 
possible that bilirubin might be bound to proteins in the damaged neurons thus 
prevented from reaching a toxic level. For instance, bilirubin has been shown to 
bind to the lipocalin apolipoprotein D (apoD) (Peitsch and Boguski 1990), and 
induction of apoD in injured neurons after kainate treatment (Ong et al. 1997) 
might attenuate any excessive rise in bilirubin in these neurons. Bilirubin may 
also protect astrocytes from its own toxicity by inducing up-regulation and 
translocation of the efflux pump, multidrug resistance-associated protein 1 (Mrp1) 
(Gennuso et al. 2004). 
The other by-product of the HO catalyzed reaction is iron. In our previous 
study, we observed an increasing concentration of iron in the degenerating 
hippocampus (Ong et al. 1999; Wang et al. 2002). One possibility is that 
increased breakdown of heme proteins by HO could have resulted in increased 
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iron accumulation in the hippocampus. However, when the time course of HO 
and bilirubin induction was compared with that of iron accumulation, it was found 
that HO-1 enzyme level and activity (as evidenced by bilirubin) had decreased by 
about one month, whereas iron accumulation continued beyond that time. It is 
thus unlikely that HO-1 activity could have accounted for the increase in iron 















 Abnormally high levels of iron concentration and oxidative stress have 
been demonstrated in a number of neurodegenerative disorders, such as 
Alzheimer’s disease (AD) and Parkinson’s disease (PD). The increased iron has 
been implicated as a major generator of reactive oxygen species (ROS), which 
can cause neuronal death in neurodegenerative diseases. However, the 
mechanism of misregulation of iron in neurodegeneration is still not clear. 
Previous studies have shown an increase in iron in the rat hippocampus after 
kainate induced neuronal injury, a model of neurodegeneration. This suggests 
that abnormal expression of iron handling proteins may be involved in iron 
accumulation in the degenerating hippocampus.  The present study was carried 
out to elucidate the expression of iron handling proteins such as DMT1 isoforms, 
iron regulatory proteins (IRPs), and ferritin in the kainate lesioned hippocampus.  
        DMT1 is a recently discovered metal transporter which mediates active 
transport of iron. Using an antibody to DMT1, immunohistochemistry, Turnbull’s 
blue stain and electron microscopy, the distribution of DMT1 was elucidated in 
monkey basal ganglia. Regions such as the caudate nucleus, putamen, and 
substantia nigra pars reticulata contained dense staining of DMT1 in astrocytic 
processes, and were also observed to contain large numbers of ferrous iron 
granules. The high levels of DMT1 in these regions may account for the high 
levels of iron in these regions, indicating that DMT1 may play an important role in 
iron uptake in brain. However, this data doesn’t show whether DMT1 was 
involved in iron accumulation after kainate induced neuronal injury. There are at 
least two isoforms of DMT1 with or without an iron response element (IRE) (+IRE 
 120
and –IRE isoforms respectively). The expression of the +IRE form of DMT1 can 
be regulated by IRPs. Therefore, we further investigated the distribution of IRPs 
and DMT1 isoforms, and any correlation between IRPs and DMT1 isoforms in 
the rat hippocampus after kainate lesion. A sustained, upregulation of IRP1, 
IRP2, DMT1 and -IRE DMT1 protein was detected in the kainate lesioned 
hippocampus by Western blot and immunohistochemical analyses up to 2 
months postinjection. Double immunofluorescence labeling showed that IRP1, 
IRP2, DMT1 and -IRE DMT1 were mostly expressed in GFAP positive 
astrocytes. The increased IRPs expression could lead to increased expression of 
the +IRE form of DMT1. On the other hand, the increased expression of the -IRE 
DMT1 indicates that transcription factors acting on putative AP-1, NF-κB binding 
sites, or γ-interferon responsive elements on the DMT1 promoter may also play a 
role in upregulating the expression of the transporter. This could lead to 
increased iron influx into the brain areas undergoing neurodegeneration, and 
might be a factor contributing to neuronal damage after the excitotoxic injury. 
      Other than DMT1 and IRPs, the expression of the iron storage protein ferritin 
was also elucidated in kainate lesioned hippocampus. An increase in ferritin, 
ferric iron and ferrous iron were observed in microglia and oligodendrocytes in 
the kainate-lesioned hippocampus. An increase in iron, together with a reduced 
expression of iron binding proteins ferritin particularly at later time intervals after 
kainate lesions, could result in some of the iron being present in the ferrous form. 
This is the form which is capable of generation of free radicals, and it is 
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postulated that this may be a factor in aggravating neuronal injury, at long time 
intervals after kainate induced neurodegeneration.  
Recent studies show that two iron exporters, ferroportin-1(FP) and 
ceruloplasmin (Cp) are required for iron efflux from neural cells. The present 
study showed increased expression of the iron transporters, ferroportin-1 and 
ceruloplasmin after kainate injection. The upregulation of these proteins may 
result in iron efflux from astrocytes to other neural cells such as neurons, 
microglia, oligodendracytes, resulting in further damage to the brain. 
 Heme oxygenase-1 can cleave the heme molecule to produce free ferrous 
iron and plays an important role in iron homeostasis. The prsent study shows that 
both increased HO-1 and bilirubin, the product of HO-1 catalyzed reactions, were 
observed in damaged neurons at early time intervals, and astrocytes at later time 
intervals after kainate injection. It was found that the tin protoporphyrin (SnPP, an 
inhibitor of HO) treated rats showed significantly less surviving neurons in the 
kainate lesioned hippocampus compared to the saline injected rats, indicating 
that HO-1 induction had a net protective effect on neurons in the kainate model 
of excitotoxic injury, and that HO-1 activity may not account for the increase in 
iron accumulation in the kainate lesioned hippocampus at late time intervals. 
 The results from the study shed light on the misregulation of iron handling 
proteins in kainite-induced neuronal injury, and are useful for further 
understanding the mechanism of iron accumulation involved in the pathobiology 
of neurodegeneration. These also provide clues to the development of 
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pharmaceutical strategies to treat neurodegenerative disorders, in which iron and 
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 Table 1. 1. Staining intensities for DMT1 and number of ferrous iron granules in 
different portions of the basal ganglia.  
 
 CAU PUT GPE GPI STN SNC SNR 
DMT1 staining 
intensity 46+7 40+5 18+3 7+4 11+13 24+13 47+11 
Number of Fe2+ 
granules/mm2 326+22 242+48 551+39 451+39 75+22 117+31 443+48 
 
CAU: caudate nucleus, PUT: putamen, GPE: globus pallidus externa, GPI: 
globus pallidus interna, STN: subthalamic nucleus,  SNC: substantia nigra 
compacta, SNR: substantia nigra reticulata, Differences in staining intensity or 
number of granules were analyzed by 1 way ANOVA and Bonferrroni’s multiple 
comparison posthoc test. Statistically significant differences are listed below (p < 
0.05): DMT1 staining intensity: CAU vs GPE, GPI, TH, STN, SNC; PUT vs GPE, 
GPI, STN, SNC; GPE vs CAU, PUT, SNR; GPI vs CAU, PUT, SNR; TH vs CAU, 
SNR; STN vs CAU, PUT, SNR; SNC vs CAU, SNR; SNR vs GPE, GPI,  STN, 
SNC. Number of Fe 2+ granules: CAU vs PUT, GPE, GPI,  STN, SNC, SNR; PUT 
vs CAU, GPE, GPI,  STN, SNC, SNR; GPE vs CAU, PUT, GPI,  STN, SNC, 
SNR; GPI vs CAU, PUT, GPE,  STN, SNC; TH vs CAU, PUT, GPE, GPI, SNR; 
STN vs CAU, PUT, GPE, GPI, SNR; SNC vs CAU, PUT, GPE, GPI, SNR; SNR 
vs CAU, PUT, GPE,  STN, SNC. 
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 Table 1. 2 
Number of DMT1, GFAP, or double immunolabeled cells, and percentages of 
double labeled cells, in different portions of the basal ganglia.  
 







CAU 1144+118 1322+119 1127+121 98.5+2.4% 85.3+1.9% 
PUT 1069+162 1107+154 1037+145 97+2.5% 93.6+2.2% 
GPE 154+16 182+26 143+15 93.5+2.3% 79+2.7% 
GPI 162+6 193+11 160+6 98.3+3.5% 83+4.1% 
STN 380+79 413+55 48+7 12.6+2.8% 11.6+2.5% 
SNC 569+65 853+83 102+17 17.9+3.9% 12.0+2.9% 
SNR 962+105 830+116 756+129 93.1+6.0% 86.5+3.4% 
 
The numbers in the first three columns indicate mean + standard deviation of 
cells / mm2. The numbers in the next two columns indicate mean + standard 




Fig. 1. 1. A: caudate nucleus (CAU), showing dense DMT1 staining in the 
neuropil. Few cell bodies are labeled. B: higher magnification of the caudate 
nucleus (CAU), showing dense staining in the neuropil (asterisk) and staining in 
astrocytic end feet around blood vessels (arrow). C: putamen (PUT) and globus 
pallidus externa (GPE), showing dense DMT1 staining in the putamen, but light 
staining in the globus pallidus externa. Diamonds indicate boundary between 
putamen and globus pallidus externa. D: higher magnification of the putamen 
(PUT) showing dense staining in the neuropil (asterisk) and staining in astrocytic 
end feet around blood vessels (arrow). E: higher magnification of the globus 
pallidus externa (GPE), showing a similar astrocytic staining around blood 
vessels (arrows). Scale: A, C = 75μm, B, D, E = 30μm. 
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Fig. 1. 1 
 １５９
Fig. 1. 2. A: subthalamic nucleus (STN, outlined by diamonds), showing light 
labeling of neuronal cell bodies (arrows), and light labeling of the neuropil. B: 
higher magnification of the subthalamic nucleus (STN), showing light labeling of 
neuronal cell bodies (arrows), and light staining of the neuropil (asterisk). C: 
substantia nigra pars compacta (SNC) and pars reticulata (SNR), showing 
labeling of neuronal cell bodies but light labeling of the neuropil in the pars 
compacta, but dense staining of the neuropil in the pars reticulata. D: higher 
magnification of the substantia nigra pars compacta (SNC), showing moderate 
labeling of neuronal cell bodies (arrows) E: higher magnification of the substantia 
nigra pars reticulata (SNR) showing dense staining of the neuropil (asterisk) and 
staining in astrocytic end feet (arrow). F: section through the substantia nigra 
pars reticulata (SNR) incubated antigen-absorbed antibody, showing absence of 
staining. Scale: A, C = 120μm, B, D, E, F = 30μm. 
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Fig. 1. 2     
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Fig. 1. 3. A: light micrograph of a DMT1 immunostained section through the 
substantia nigra showing light labeling of the substantia nigra compacta (SNC), 
but dense staining of the substantia nigra reticulata (SNR, outlined by diamonds). 
The cerebral peduncles (CP) are not labeled. B: Turnbull’s blue stained section 
showing dense staining in the substantia nigra pars reticulata (SNR, outlined by 
diamonds), but absence of dense granules in the substantia nigra pars compacta 
(SNC) and cerebral peduncles (CP). C: higher magnification of the junction 
between the substantia nigra pars compacta (SNC) and the substantia nigra pars 
reticulata (SNR). The neuromelanin containing neurons in the substantia nigra 
compacta (thick arrows) are situated away from the ferrous iron granules in the 
pars reticulata (thin arrows) D,E: ferrous iron containing granules are also 
observed in the caudate nucleus (CAU) (D, arrow) and the putamen (PUT) (E, 







Fig. 1. 3 
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Fig. 1. 4. Correlation between staining intensity for DMT1 and the number of 
ferrous iron granules in different nuclei of the basal ganglia.  
 




























In general, regions that stained densely for DMT1 were also those that contain 
large numbers of ferrous iron granules. The exceptions were the globus pallidus 
externa and interna, where light DMT1 staining, but large numbers of ferrous iron 
granules were observed. When these were excluded from analysis, a significant 
correlation was observed between the intensity of DMT1 staining and number of 
ferrous iron granules in the different nuclei, by linear correlation analysis 
(R2=0.8708, p <0.01). 
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 Fig. 1. 5. Electron micrographs of DMT1 immunolabeled sections through the 
caudate nucleus (A, B) and substantia nigra pars reticulata (C). A: the caudate 
nucleus contains unlabeled neuronal cell bodies (N), but large numbers of 
labeled processes in the neuropil (arrows). B: some of the labeled processes in 
the caudate nucleus were observed to form astrocytic end feet (AS) around blood 
vessels. Arrows indicate reaction product. L: lumen of blood vessel. C: light 
labeling (arrows) is observed in astrocytic cell bodies (AS) in the substantia nigra 
pars reticulata. F: dense bundle of glial filament in the astrocyte. Scale: A = 
1.5mm, B = 250nm, C = 700nm. 
 
 １６５
Fig. 1. 5 
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Fig. 1. 6. Electron micrographs of Turnbull’s blue stained sections through the 




Dense ferrous iron positive granules (arrows) are present in oligodendrocytes 
(O). The latter had regular cytoplasmic outlines, an eccentrically placed nucleus 
within the cell body, dense heterochromatin clumps in the nucleus, and absence 
of dense bundles of glial filaments characteristic of astrocytes. Scale = 700nm. 
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Fig. 1. 7.Double immunofluorescence labeling for DMT1 and GFAP. Red channel 
shows DMT1 labeling; green channel shows GFAP labeling. (A) Caudate nucleus, 
showing DMT1 processes which are double labeled with GFAP (yellow 
processes, indicated by arrows). V, blood vessel. (B) Subthalamic nucleus, 
showing DMT1 positive neurons (arrows) which are not double labeled with 
GFAP. (C) Substantia nigra pars compacta, showing DMT1 positive neurons 
(arrows) which are not double labeled with GFAP. (D) Substantia nigra pars 
reticulata, showing DMT1 processes which are double labeled with GFAP 
(yellow processes, indicated by arrows). V:  blood vessel. Scale bar: 20 μm. 
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Table 2. 1. IRP1 / IRP2 / DMT1 (+IRE and –IRE) / -IRE DMT1 immunolabeled 
glial cells in field CA1 of saline- or kainate-injected rats.  
 
 S 3D 1W 2W 4W 8W 
IRP1 0 250+75 423+99 625+129 575+86 487+83 
IRP2 0 338+75 869+101 1188+149 1125+170 907+109 
DMT1 150+41 371+62 954+128 1466+195 1204+144 975+96 
DMT1 (-) 0 262+85 521+92 700+122 579+116 525+86 
 
S, 3D, 1-8W indicate saline-injected, or 3 days, and 1-8 weeks post-kainate 
injected. DMT1 (+) and DMT (-) refer to +IRE DMT1 and -IRE DMT1. The 
numbers indicate mean + standard deviation of cells / mm2. One-way ANOVA 
with Bonferroni's multiple comparison post-hoc test. Statistically significant 
differences are listed below (P < 0.05): IRP1: S vs 1W, 2W, 4W, 8W; 3D vs 2W, 
4W, 8W; 1W vs 2W. IRP2: S vs 3D, 1W, 2W, 4W, 8W; 3D vs 1W, 2W, 4W, 8W; 
1W vs 2W. DMT1: S vs 1W, 2W, 4W, 8W; 3D vs 1W, 2W, 4W, 8W; 1W vs 2W; 
2W vs 8W. DMT1 (-): S vs 3D, 1W, 2W, 4W, 8W; 3D vs 1W, 2W, 4W, 8W.  
  
 １７０
Table 2. 2. Number and percentages of double labeled cells, in 2 week post-
kainate injected rats.  
 
The first three columns indicate mean + standard deviation of cells / mm2. The 
last two columns indicate mean + standard deviation of percentages of double 
labeled cells.  
 
First labeling 
and number (1) 
Second labeling 





IRP1 601+113 GFAP 905+143 546+124 89.2+6.4 59.3+4.1 
IRP1 658+97 OX42 728+121 63+31 10.2+7.6 8.9+7 
IRP2 1146+165 GFAP 1124+162 1104+156 91.6+1.5 93.3+3.7 
IRP2 1173+186 OX42 878+138 0 0 0 
DMT1 1254+127 GFAP 1207+116 1159+128 92+0.9 96.4+6 
DMT1 1214+142 OX42 967+163 0 0 0 
DMT1 (-) 632+134 GFAP 963+198 630+104 88.7+4.2 65.9+2.9 
DMT1 (-) 663+106 OX42 891+203 69+25 10.1+3.3 7.5+2.5 
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 Fig. 2.1 Western blot analysis of homogenates of hippocampus from rats that 
had been injected with saline or kainate 1 week previously. The antibodies to 
IRP1, IRP2, DMT1 (+IRE and –IRE) or -IRE DMT1 detect major bands at 98 kDa, 
100 kDa, 50 kDa and 60 kDa respectively, consistent with the expected 
molecular weights of these proteins. S-1W, KA-1W, DMT1 (+/ -) and DMT (-) 
indicate 1 week post saline-injection, 1w post kainate-injection, DMT1 (+IRE and 
-IRE) and - IRE DMT1.  
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Fig. 2. 2. Density ratios of the IRP1, IRP2, DMT1 (+IRE and -IRE)  or -IRE DMT1 
















































 S, KA, DMT1 (+/ -) and DMT (-) indicate saline-injected and 1 week post-kainate 
injection, DMT1 (+IRE and -IRE) and - IRE DMT1 respectively. n = 3 in each 
case. Analyzed by Student’s t-test. Asterisks indicate significant differences 
between the kainate and saline injected rats (p < 0.05). 
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Fig. 2. 3. A-D: Light micrographs of DMT1 (+IRE and -IRE), -IRE DMT1, IRP1 or 
IRP2 immunolabeled adjacent sections through field CA1 of the hippocampus, 
from a saline injected rat. Little immunoreactivity to IRP1 (A), IRP2 (B) or –IRE 
DMT1 (D) is present (asterisks). DMT1(+IRE and -IRE)(C) immunoreactivity is 
observed in occasional astrocytes (arrows). E-H: Adjacent sections through field 
CA1 of the hippocampus, from a rat that had been injected with kainate 3 days 
earlier. Little immunoreactivity to IRP1 (E), IRP2 (F) or –IRE DMT1 (H) is present 
in the degenerating CA field at this time (asterisks). DMT1 (G) immunoreactivity 
is observed in occasional astrocytes (arrows). Scale = 50 µm. 
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Fig. 2. 3 
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Fig. 2. 4. A-D: Light micrographs of DMT1, -IRE DMT1, IRP1 or IRP2 
immunolabeled adjacent sections through field CA1 of the hippocampus, from a 
rat that had been injected with kainate 2 weeks earlier. An increase in IRP1 (A), 
IRP2 (B) DMT1(+IRE and -IRE) (C) or -IRE DMT1 (D) staining is observed in glial 
cells, in the degenerating CA field (arrows). Inset in B: control section incubated 
with antigen preabsorbed IRP2 antibody, showing absence of labeling. Inset in D: 
control section incubated with antigen preabsorbed –IRE DMT1 antibody, 
showing absence of labeling. E-H: Adjacent sections through field CA1 of the 
hippocampus, from a rat that had been injected with kainate 8 weeks earlier. 
IRP1 (E), IRP2 (F) DMT1(+IRE and -IRE) (G) or -IRE DMT1 (H) staining is still 
visible in the degenerating CA field at this time (arrows). Scale = 50 µm. 
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Fig. 2. 4 
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Fig. 2. 5. Electron micrographs of IRP1 (A), IRP2 (B), DMT1(+IRE and -IRE) (C) 
or -IRE DMT1 (D) positive glial cells (AS) in the degenerating hippocampus, from 
rats that had been injected with kainate 2 weeks previously. Arrows indicates 
immunoreaction product. The nucleus of the labeled cells contains evenly 
dispersed fine heterochromatin clumps, and absence of marginated 
heterochromatin on the inner aspect of the nuclear envelope. The cytoplasm 
contains dense bundles of glial filaments (F). They thus had features of 




Fig. 2. 6. Double immunofluorescence labeling from sections through the 
degenerating field CA1 of the hippocampus, from rats that have been injected 
with kainate 2 weeks earlier. A, B, C: red (IRP1 label), green (GFAP label) and 
merged channels from a section that had been double immunostained for IRP1 
and GFAP. D,E,F: red (IRP2), green (GFAP) and merged channels from a 
section that had been double immunostained for IRP2 and GFAP. G, H, I: red 
(DMT1 (+IRE and -IRE) label), green (GFAP label) and merged panels from a 
section that had been double immunostained for the DMT1 isoforms and GFAP. 
J, K, L: red (-IRE DMT1 label), green (GFAP label) and merged channels from a 
section that had been double immunostained for the DMT1 (-IRE) isoform and 
GFAP. Most of the cells in panels A, D, G, J are double labeled with those in B, 
E, H, K respectively indicating that they were astrocytes (arrows). Scale = 20 µm. 
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Fig. 2. 6 
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 Table 3. 1. Number of ferritin, glial marker, ferric iron, and ferrous iron positive 
cells, double immunolabeled cells, and percentages of double labeled cells, in 2 
weeks and 8 weeks post-kainate injected rats.  
     First labeling     and number (1) 
  Second labeling  
  and number (2) Double(3) (2)-(3) 
Double/   
1st % 
Double/ 
2nd  % 
Ferritin 895+215 OX42 883+341 754+204 129+97 85.8+11 84.4+7.8 
Ferritin 915+93 CNP 635+80 54+31 581+59 5.9+3.4 8.4+4.7 
Ferritin 881+165 GFAP 792+130 0 792+130 0 0 
Ferritin 882+144 Fe3+  354+59 * 190+49 * 156+54 * 20.1+7.7 * 55.6+8.8 
Ferritin 924+185 Fe2+  140+88 * 74+63 * 66+40 * 9.2.+6.2 * 
 
2W and 8W refer to 2 and 8 weeks post-kainate injection. The numbers in the 
first three columns indicate mean + standard deviation of cells / mm2. The 
numbers in the next two columns indicate mean + standard deviation of 
percentages of double labeled cells. * indicates significant differences between 2 
weeks and 8 weeks post-kainate injected rats for particular set of double labeling 
reactions (p< 0.05). 
46.1+6.8 
OX42 882+144 Fe3+  354+59 * 190+49 * 164+23 * 21.9+6.4 * 52.4+4.7 
OX42 808+156 Fe2+  140+100 * 79+52 * 61+50 * 10.9+8.1 * 57.1+4.7 
CNPase 676+106 Fe3+  380+106 * 173+63 207+42 * 25.5 +8 44.5+6.4 
2W 
CNPase 726+121 Fe2+  127+75 * 53+35 * 73+44 * 7.8+6.3 * 41.8+7.4 
Ferritin 1024+335 OX42 1088+353 987+380 101+36 80.4+11 89.6+9.4 
Ferritin 1020+234 CNP 941+289 98+25 843+196 9.6+2.1 10.5+2.9 
Ferritin 1003+219 GFAP 922+224 0 922+224 0 0 
Ferritin 998+107 Fe3+  948+175 * 528+93 * 420+82 * 52.7+6.5 * 52.3+4.9 
Ferritin 974+145 Fe2+  454+142 * 215+83 * 239+63 * 23.1+2 * 46.2+5.5 
OX42 899+141 Fe3+  940+209 * 503+94 * 437+122 * 55.9+5.3 * 54.5+8 
OX42 849+210 Fe2+  470+133 * 272+103 * 198+40 * 35.2+6.3 * 58.2+1.4 
CNPase 684+147 Fe3+  784+186 * 363+130 420+82 * 51.5+8.6  45.2+4.6 
8W 
CNPase 720+103 Fe2+  486+203 * 202+100 * 284+104 * 29+3 * 39.1+5.6 
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Fig. 3. 1. Numbers of ferric iron, ferrous iron, or ferritin positive cells in field CA1, 























1D, 3D, 1W, 2W, 4W, 8W and 12W indicate 1 day, 3 days, 1, 2, 4, 8 and 12 
weeks postkainate injection, respectively. S or K refers to saline- or 
kainateinjected rats. The Y-axis indicates the number of stained cells per mm2. 
Error bars indicate standard deviations. n=4 at each postinjection time interval. 
Ferritin immunoreactivity peaked at four weeks post-kainate injection and 
decreased eight and twelve weeks post-injection. 
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Fig.3. 2. Adjacent section through field CA1 of the saline-injected hippocampus. 
A, B are sections labeled by Perl’s stain for ferric iron (A) or Turnbull’s blue stain 
for ferrous iron (B), showing no staining. C is a section immunostained for ferritin, 
showing only occasional labeled cells (arrow). Adjacent sections through field 
CA1 of the hippocampus, from a rat three days postkainate injection. D is Nissl 
stained section, showing loss of pyramidal neurons in field CA1 (arrow). E is 
section immunostained for ferritin, showing ferritin-labeled cells with irregular cell 
outlines (arrows). F: Ferritin labeled cells with irregular cell outlines (arrow), from 







Fig. 3. 3. Adjacent section through field CA1 of the rat hippocampus, from a rat 
that had been injected with kainate one month earlier. A: section stained for ferric 
iron showing an increase in number of iron positive cells in the degenerating CA 
field (arrows) (c.f. Fig. 3. 1). B: section stained for ferrous iron, showing a small 
increase in number of positive cells in the CA fields at this time (arrows). C: 
section immunostained for ferritin, showing an increased number of ferritin 
positive cells in the degenerating CA field (arrows). Adjacent section through field 
CA1 of the rat hippocampus, from a rat that had been injected with kainate two 
months earlier. D: section stained for ferric iron showing an increase in number of 
iron positive cells in the degenerating CA field (arrows) (c.f. Fig. 3. 1). E: section 
stained for ferrous iron, showing further increase in number of positive cells in the 
CA fields (arrows). compared to that at 4 weeks postinjection (c.f. Fig. 3. 3B). F: 
section immunostained for ferritin, showing decreased numbers of ferritin positive 
cells in the degenerating CA field, compared to that at 4 weeks postinjection 
(arrows). These contained thicker processes, compared to the cells in saline 





Fig. 3. 3 
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Fig. 3. 4. Electron micrographs of sections through field CA1 from a rat, which 
had been injected with kainate two weeks earlier. A: a ferritin positive microglia 
(M), next to an unlabelled astrocytic process (AS). The nucleus of the microglia 
contains dense clumps of heterochromatin on the inner aspect of the nuclear 
envelope. Arrows indicate immunoreaction product in the cytoplasm of the 
microglia. F: unlabelled glial filaments in the astrocyte. B: higher magnification of 
a labeled microglia. Ferritin label (arrow) is associated with the endoplasmic 
reticulum (ER). C: ferritin labeling (arrow) is also present in endothelial cells (E) 
of blood vessels in the degenerating CA field. L: lumen of blood vessel. Scale: A 
= 0.5µm, B, C = 1µm. 
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Fig. 3. 4 
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Fig. 3. 5. Double labeling for ferritin and glial markers or Perl's stain / Turnbull's 
blue stain. A-D: Double immunofluorescence labeling. A, B, C: sections through 
the degenerating field CA1 of the hippocampus, from a rat, which had been 
injected with kainate 2 weeks earlier. A: Ferritin labeling (red) are double labeled 
for OX42 (green). The merged double-labeled color is yellow (arrows). B: Ferritin 
labeling (red, arrows) are unlabeled for CNPase (green). C: Ferritin labeling (red, 
arrows) are unlabeled for GFAP (green). D: sections through the degenerating 
field CA1 of the hippocampus, from a rat, which had been injected with kainate 8 
weeks earlier. Ferritin labeling (red) are double labeled for OX42 (green). The 
merged double-labeled color is yellow (arrows). E, F: Double labeling with 
immunocytochemistry for ferritin and Perl's stain or Turnbull's blue stain. E, F: 
sections through the degenerating field CA1 of the hippocampus from a 8 weeks 
post-kainate injected rat, showed some ferritin positive cells (brown, black 
arrows) were not double labeled with Perl's stain (blue, black arrowhead) (E) or 
Turnbull's blue stain (blue, arrowhead) (F). The white arrows showed the double 












Table 4. 1. Number of FP / Cp/+IRE DMT1 / -IRE DMT1 stained glial cells in field 
CA1 of saline- or kainate-injected rats.  
 
 S 3D 1W 2W 4W 8W 
F P 16+19 123+31 347+68 470+68 346+63  247+57 
C p 17+15 99+27 380+57 437+99 355+56  231+47 
+IRE DMT1 58+31 181+42 478+73  734+141 528+83  363+97 
- IRE DMT1 66+27 140+49 454+109 718+135 511+60  347+57 
 
S, 3D, 1-12W indicate saline injection, 3 days, and 1-8 weeks after kainate 
injection. The numbers indicate mean + standard deviation of cells / mm2. One-
way ANOVA with Bonferroni's multiple comparison post-hoc test. Statistically 
significant differences are listed below (p < 0.05): FP : S vs 3D, 1W, 2W, 4W, 8W; 
3D vs 2W, 4W; 2W vs 8W. Cp: S vs 3D, 1W, 2W, 4W, 8W; 3D vs 1W, 2W, 4W; 
1W vs 8W; 2W vs 8W. +IRE DMT1: S vs 1W, 2W, 4W, 8W; 3D vs 1W, 2W, 4W; 
1W vs 2W; 2W vs 4W, 8W. -IRE DMT1: S vs 1W, 2W, 4W, 8W; 3D vs 1W, 2W, 
4W, 8W; 1W vs 2W, 2W vs 4W, 8W. At 2-week, 4-week postinjection, there are 
significant differences as follows (asterisk, p < 0.05): FP vs +IRE DMT1, -IRE 
DMT1;  Cp vs +IRE DMT1, -IRE DMT1. 
 １９２
Fig. 4. 1.  Western blot analysis of homogenates of rat hippocampus of a saline-
injection and a kainate-injection. The antibody to FP and Cp detected single band 
at ~62 kDa, ~136 kDa respectively. The antibody to +IRE DMT1, -IRE DMT1  
both detected  bands at ~60 kDa, ~50 kDa, ~45 kDa. Increased the density of 
detected bands were observed in kainate injected rats, compared to saline-
injected rats. S-1W and KA-1W refer to 1 week post saline-injection and 1 week 
post kainate-injection respectively. 
 １９３
 Fig. 4. 1 
 
 １９４
Fig. 4. 2. A-D: Light micrographs of FP, Cp, +IRE DMT1 or -IRE DMT1 
immunolabeled adjacent sections through field CA1 of the hippocampus, from a 
saline injected rat. No or little FP (A), Cp (B), +IRE DMT1 (C) and –IRE DMT1 (D) 
immunoreactivity was observed in the hippocampus of saline injected rats.  
Medial Cp (B) immunoreactivity was observed in pyramidal neurons in 
hippocampus (arrows). E-H: Adjacent sections through field CA1 of the 
hippocampus, from a rat that had been injected with kainate three days earlier. A 
little increase in FP (E), Cp (F) , +IRE DMT1 (H)  and –IRE DMT1 (G) 
immunoreactivity was observed in glial cells in the CA1 fields at this time, and 
medical Cp (F) immunoreactivity was observed in degenerating pyramidal 
neurons at this time (arrows). Asterisk indicates no or little staining in the 
degenerating CA field. Scale = 50 µm. 
 １９５
Fig. 4. 2 
 １９６
Fig. 4. 3. A-D: Light micrographs of FP, Cp, +IRE DMT1 or -IRE DMT1 
immunolabeled adjacent sections through field CA1 of the hippocampus, from a 
rat that had been injected with kainate two weeks earlier. An further increase in 
FP (A), Cp (B), +IRE DMT1 (C) or –IRE DMT1 (D) staining was observed in the 
degenerating CA fields at this time. The FP, Cp, +IRE DMT1 or -IRE DMT1 
immunoreactivity was observed in a population of glial cells with large diameter 
processes that tapered gradually from the cell bodies, characteristic of astrocytes. 
The increased number of the FP and Cp positive cells was significantly smaller 
that of the +IRE DMT1 and –IRE DMT1 positive cells. E-H: Adjacent sections 
through field CA1 of the hippocampus, from a rat that had been injected with 
kainate 8 weeks earlier. A minor decrease in FP (E), Cp (F), +IRE DMT1 (G) or –
IRE DMT1 (H) staining was observed at this time, compared to four weeks 
postinjection. Scale = 50 µm. 
 １９７
Fig. 4. 3 
 １９８
Fig. 4. 4. Electron micrographs of FP and Cp positive cells in the degenerating 
hippocampus. Section from a rat that had been injected with kainate two weeks 
previously, FP (A, B ) and Cp (C,D) positive cells have feature of astrocytes (AS), 
which has a large cell body with an irregular outline. The nucleus contains evenly 
dispersed fine heterochromatin clumps, and absence of marginated 
heterochromatin on the inner aspect of the nuclear envelope. Some of the 
labeled processes were observed to form end feet around blood vessels  (B,D) 
but not obvious labeling was observed in endothelial cells. The cytoplasm 
contains dense bundles of glial filaments (F).  arrows indicate the 
immunoreaction product. L : lumen of blood vessel.  Scale = 1 µm. 
 １９９
Fig. 4. 4 
 
 ２００
Fig. 4. 5. Double immunofluorescence labeling of sections through the 
degenerating field CA1 of the hippocampus, from a rat, which had been injected 
with kainate 2 weeks earlier. A-C: The cells which are positive for FP (A, red) are 
double labeled for GFAP (B, green), indicating that they are astrocytes. The 
merged double-labeled color is yellow (C, arrows). D-F: The cells which are 
positive for Cp (D, red) are double labeled for GFAP (E, green), indicating that 
they are astrocytes. The merged double-labeled color is yellow (F, arrows).  
Scale A-D = 20µm. 
 ２０１
Fig. 4. 5 
 
 ２０２
Table 5. 1. Number of Nissl stained cells and HO-1 / bilirubin / ferric / ferrous 
iron-positive cells in field CA1 of saline- or kainate-injected rats.  
 
 S 1D 3D 1W 2W 4W 8W 12W 
Nissl 2863+220 2640+157 1031+191 N/A N/A N/A N/A N/A 
HO-1-Neu 0 345+53 420+66 400+56 0 0 0 0 
HO-1-As 0 15+19 25+30 480+78 805+137 1045+192 410+123 190+68 
BR-Neu 0 375+44 405+33 350+59 0 0 0 0 
BR-As 0 0 15+19 490+85 1245+100 1375+179 685+68 310+84 
1135+23
8 Fe III 0 0 0 193+75 310+49 613+70 988+67 
Fe II 0 0 0 0 103+29 330+46 423+117 437+156
 
The numbers indicate mean + standard deviation of cells / mm2 .  Nissl, HO-1, 
BR, Fe III, Fe II, Neu, As and S indicate Nissl staining, HO-1 staining, bilirubin 
staining, ferric iron staining, ferrous iron staining, neurons, astrocytes and saline, 
respectively. 1D, 3D, 1-12W indicate 1 and 3 days, and 1-12 weeks after kainate 
injection. NA refers to not applicable.  
 ２０３
  
Fig. 5. 1. Numbers of HO-1 / bilirubin / ferric / ferrous iron-positive cells in field 
CA1 of saline or kainate-injected rats. CA1, HO-1, BR, Fe III, Fe II, Neu, As and 
S indicate field CA1, HO-1 staining, bilirubin staining, ferric iron staining, ferrous 
iron staining, neurons, astrocytes and saline, respectively. 1D, 3D, 1-12W 



































































































Fig. 5. 2. Light micrographs of HO-1 and bilirubin immunolabeled sections from 
the saline-injected hippocampus (A,B) and the one day post-kainate lesioned 
hippocampus (C-F). A, B: Very little HO-1 (A) or bilirubin (B) staining is present in 
the salin-injected hippocampus. Arrows indicate cell bodies of pyramidal 
neurons. C: An increase in HO-1 staining is observed in pyramidal neurons 
(arrows) in field CA1. D: HO-1 staining is also observed in isolated astrocytes in 
the molecular layer of the dentate gyrus (arrows), and occasional dentate granule 
neurons (double arrows). E: An increase in bilirubin staining is observed in 
pyramidal neurons (arrows) in field CA1. F: In contrast to the scattered HO-1 
staining, no increase in bilirubin staining is observed in the dentate gyrus 
(asterisk). Scale = 150 µm. 
 ２０６
Fig. 5. 2 
 
 ２０７
Fig. 5. 3. Light micrographs of Nissl-stained and HO-1 and bilirubin-
immunolabeled sections from the three day post-kainate injected hippocampus. 
A: Nissl stained section, showing loss of pyramidal neurons in field CA1 (arrows). 
B,C: An increase in HO-1 (B) and bilirubin (C) staining is also observed in 
pyramidal neurons (arrows) in field CA1. D: Higher magnification, showing dense 
bilirubin immunoreactivity in field CA1 pyramidal neurons (arrows). The staining 
intensity is greater than that of reactive astrocytes (see Fig. 5. 5C). Scale: A-C = 
150 µm, D = 40 µm. 
 
 ２０８
Fig. 5. 3 
 
 ２０９
Fig. 5. 4. Bilirubin immunoreactivity in pyramidal neurons and astrocytes in the 




















The Y-axis indicates intensity of bilirubin immunoreactivity in neurons (Neu) or 
astrocytes (As) in densitometric units, and X-axis indicates different postinjection 
time intervals. Neu and As indicate neurons and  astrocytes. 1D, 3D, 1-12W 
indicate 1 and 3 days, and 1-12 weeks after kainate injection. Error bars indicate 
standard deviations. The intensity of staining of neurons is greater than that of 
astrocytes. One-way ANOVA with Bonferroni's multiple comparison post-hoc test. 
Statistically significant differences are listed below (p < 0.05): 1D-Neu vs 1W-As, 
2W-As, 4W-As, 8W-As, 12W-As; 3D-Neu vs 1W-As, 2W-As, 4W-As, 8W-As, 
12W-As; 1W-Neu vs 1W-As, 2W-As, 4W-As, 8W-As, 12W-As.  
 
 ２１０
Fig. 5. 5. Light micrographs of HO-1 and bilirubin immunolabeled sections 
through field CA1, from rats at two to eight weeks after kainate injection. A, B: 
HO-1 (A) and bilirubin (B) immunostained sections from the same two weeks 
post-injection rat, showing light staining in astrocytes (arrows). C: Higher 
magnification of a cell from the same section as B, showing staining in astrocytes 
(arrows). The staining intensity is less than that of neurons (see Fig. 5. 3D, 
above). D: Bilirubin immunostained section from a four weeks postinjected rat, 
showing moderate staining in astrocytes (arrows). E, F: HO-1 and bilirubin 
immunostained section from an eight weeks postinjected rat, showing light 
staining (arrows) for HO-1 (E) and bilirubin (F). Scale: A,B,D-F = 150 µm, C =40 
µm. 
 ２１１
Fig. 5. 5 
 ２１２
Fig. 5. 6. Electron micrographs of bilirubin-positive cells in the degenerating 
hippocampus. A: Section from a rat that had been injected with kainate 3 days 
previously, immuno-positive neuron (N), showing features of injured / 
degenerating neuron. Large numbers of vacuoles (V) are visible in the 
cytoplasm. Intense bilirubin staining is observed in the cytoplasm (arrows). B: 
Section from a rat that had been injected with kainate four weeks previously, 
immuno-positive astrocytes (AS), showing features of a viable cell. It has a large 
cell body with an irregular outline. The nucleus contains evenly dispersed fine 
heterochromatin clumps, and absence of marginated heterochromatin on the 
inner aspect of the nuclear envelope. The cytoplasm contains dense bundles of 
glial filaments (F). Compared to neuron, less reaction product is present in the 
cytoplasm (arrows). Scale: A = 1 µm, B = 0.5 µm. 
 ２１３






































Systemic administration of SnPP (50 μmol/kg/day I.P.) had a deleterious effect 
on mortality as well as cell survival after kainate injection. Asterisks indicates 
significant differences between the saline-treated and SnPP-treated groups 
(p<0.01). Nissl: Nissl staining. MAP2: MAP2 immunostaining.  
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